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ABSTRACT OF THE DISSERTATION
The Impact of Interferon Regulatory Factor 3 on the Immune Response to Herpes
Simplex Virus Type 1 Infection
By
Vineet David Menachery
Doctor of Philosophy in Biology and Biomedical Sciences
(Immunology)
Washington University in St. Louis, 2010
Dr. David A. Leib & Dr. Michael S. Diamond, Co-Chairs
The type I interferon (IFN) cascade is critical in control of herpes simplex virus
type I (HSV-1) infection and relies on specific recognition molecules to rapidly signal
viral infection via interferon regulatory factor-3 (IRF-3) -dependent pathways. The
absence of these recognition molecules or the loss of IRF-3 would be predicted to render
early recognition pathways inoperative and thus impact viral infection. However,
previous results had produced contradictory results in terms of the role of IRF-3 during
HSV-1 infection. In this study, infected IRF-3-/- immune cells were found to support
increased HSV-1 replication compared to control cells. In addition, IRF-3 deficient cells
exhibited delayed type I IFN synthesis following infection and were partially restored in
the presence of exogenous IFN; blockade of the type I IFN receptor resulted in similar
titers in control and IRF-3-/- cells. Together, the data demonstrated that defective and
deficient type I IFN production in IRF-3-/- cells resulted in increased HSV-1 replication in
vitro. In vivo, IRF-3 deficiency was found to have no significant impact on HSV-1
replication in peripheral tissues following ocular challenge with a laboratory (17) or a
vii

neurovirulent strain (McKrae) of virus. However, IRF-3-/- mice were significantly more
susceptible to central nervous system infection following both peripheral and intracranial
infection with HSV-1. Increased viral replication and inflammatory cytokine production
were observed in brain tissues of IRF-3-/- mice compared to control mice. In addition, the
production of IFNβ and IFNα was delayed and reduced in IRF-3-/- brains. These data
demonstrate a critical role for IRF-3 in control of central nervous system infection
following HSV-1 challenge. Together, the data illustrate the importance of IRF-3
mediated pathways in initiating the type I IFN cascade necessary to control HSV-1
infection both in vitro and in vivo.
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Chapter I
Introduction

1

The Herpes Virus Family
Herpesviridae constitutes a family of ubiquitous viruses that infect a variety of
hosts ranging from fish to mammals (122). The nearly 130 identified members of the
herpesvirus family are divided into three subfamilies on the basis of biological properties:
Alpha-, Beta-, and Gamma- herpesviruses (165). Alphaherpesviruses, which include
herpes simplex virus type 1 (HSV-1) and herpes simplex type 2 (HSV-2), have a variable
host range, short reproductive cycle, rapid spread, and lyse host cells in vitro and in vivo.
In contrast, betaherpesviruses, which include human cytomegalovirus (HCMV) and
murine cytomegalovirus (MCMV) , have a restricted host range, a long life cycle, and
grow slowly in culture. Finally, gammaherpesviruses are restricted to the family or order
of their natural host and include Epstein Barr Virus (EBV); the members of this group
effectively replicate within immune cells especially T and B lymphocytes (165). Despite
initial classification based mainly on biological properties, nucleic acid and protein
sequence similarities have since validated grouping into these functional families.
However, each member of the herpesviridae family shares several significant properties.
The hallmark of the herpes virus family is the ability to establish latency and a
lifelong infection. Latency is characterized by limited viral gene expression, stable
maintenance of the viral genome, and the absence of infectious virions (165). While the
stimuli remain unknown, herpesviruses in the latent state are periodically induced to
reactivate causing recurrent infection in the host. The absence and reemergence of
infectious virus distinguish latency from chronic or abortive infections respectively.
Establishment of latency in varying cell types also distinguishes between the three
herpesvirus families. Alphaherpesviruses establish latency within sensory ganglia;
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betaherpesviruses establish latent infection in secretory glands, lymphoreticular cells, the
kidney, and other tissues. Finally, gammaherpeseviruses frequently establish latency in
lymphoid tissues, specifically B and T-cells.
Despite the wide host ranges, each member of the herpesvirus family also
maintains a similar structure with four distinct components: core, capsid, tegument, and
envelope (165). The inner core contains the linear double-stranded DNA genome which
is surrounded by an icosohedral capsid made up of viral proteins. The lipid envelope
makes up the outer most layer of the virion and is composed primarily of host cellular
membrane and viral glycoproteins. These viral glycoproteins are non-randomly
distributed throughout the envelope and form the spikes associated with herpes virions.
Finally, the tegument separates the envelope from the capsid; the amorphous tegument is
made up of several viral proteins that function in the host cytoplasm, nucleus, or both.
Many of these proteins are dispensable for viral replication, but appear critical for
virulence. Together, these components form herpes virions ranging in size from 120 to
nearly 300nm with tegument thickness and envelope composition contributing to the
variability in size.
In addition to similar structure, the herpesvirus family shares several common
traits during infection. Each utilizes glycoproteins within the envelope to mediate
binding, attachment, and fusion to the host cell. Upon entry, herpesviruses traffic their
genome and other components to the nucleus where viral transcription, DNA replication,
capsid formation, and packaging of viral DNA occur. Utilizing its large double-stranded
DNA genome, herpesviruses also encode a wide array of proteins involved in nucleic
acid metabolism, DNA synthesis, protein processing, and immune antagonism.
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Following DNA packaging, capsids acquire and lose a primary envelope composed of the
nuclear membrane. Finally, the tegument and envelope are acquired in the cytoplasm and
the progeny virions are prepared to exit the cell. Production of infectious herpesvirus
progeny, in contrast to latency, results in destruction of the infected host cell.

Herpes Simplex Virus Type I
The thesis work described herein focuses on infection with herpes simplex virus
type I (HSV-1), a member of the alphaherpesviridae family (165). HSV-1 is a
widespread human pathogen that has high seroprevalence in adults (222). Among the
first human herpes viruses to be discovered, HSV-1 infection has served as a research
model in numerous areas including the nervous system, membrane structure, and gene
regulation, in addition to infectious disease (164). HSV-1 infection also causes numerous
diseases in humans and is the target of on-going vaccine research (96).

Structure
Like all herpesviruses, HSV-1 is composed of the four major structural
components: genomic core, capsid, tegument, and envelope. The virus has a large doublestranded DNA genome comprised of nearly 150 kilo-base pair divided into a unique long
and unique short region (121, 163). Enclosed within the viral capsid, the genome
encodes as many as 84 unique genes involved in the viral life cycle (164). In addition to
the capsid, the viral envelope, composed of viral glycoproteins and host cell membrane,
encases the HSV-1 tegument. The tegument, which constitutes the layer between the
envelope and capsid, is released into the cytoplasm shortly after infection (132). The
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tegument is among the best-characterized and most studied groups of viral proteins and is
critically involved in HSV-1 life cycle.

Viral Replication
HSV-1 replication is divided into several major events. Infection is initiated via
attachment of viral glycoprotein C and B (gC and gB) to the cell surface, glycoprotein D
binding of cell-surface co-receptors, and fusion of the viral envelope and plasma
membrane(154, 164, 188-189, 208). Following fusion, the capsid is transported to the
nucleus and the tegument proteins are released into the cytoplasm, accompany the DNA
into the nucleus, or remain associated with the capsid (164, 205). In the nucleus, viral
transactivators, in combination with the host machinery, initiate ordered transcription of
viral genes divided into four kinetic classes (213). The α genes, the immediate early
kinetic class, consist of five viral proteins that prime the transition from cellular to viral
gene expression (164). The β genes, the early kinetic class, follow the α genes with
expression of viral proteins involved in replication of viral DNA. The γ1 genes, the leaky
late genes, can actually be expressed prior to DNA replication, but their maximal
expression is DNA replication-dependent. These γ1 genes include structural proteins,
glycoproteins, and immune antagonists. Finally, the γ2 genes, the true late structural
genes, are expressed and are dependent on viral DNA synthesis for expression.
Following γ1 gene expression, synthesis of progeny virions is initiated. The
capsid protein, a γ1 gene, localizes to the nucleus for insertion of the viral DNA (131,
164). The complete nucleocapsid then egresses through the nuclear membrane and
eventually into the golgi apparatus acquiring tegument proteins during the process.
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Within the golgi apparatus, final maturation of the viral glycoprotein occurs and the
virion is ready to infect a new cell either through release through the plasma membrane
or through direct cell-to-cell contact (164, 207). Productive HSV-1 infection results in
death of the host cell due to a variety of cellular responses to infection including changes
in host chromatin, alteration of cell membranes, and formation of intranuclear inclusion
bodies (164).

Life cycle and Latency
As mentioned earlier, the ability to establish a lifelong latent infection is the
hallmark of herpesvirus infections (165). During HSV-1 infection, the virus life cycle
begins with lytic replication in peripheral mucosal epithelia (164). The virus is then able
to enter the nerve termini and is transported through the axon in a retrograde fashion to
the sensory ganglia (105). Upon reaching the ganglia, the virus can continue a lytic
infection in neurons. Following entry into the CNS during acute primary infection HSV
can cause life-threatening encephalitis; however, the virus usually shifts to a quiescent
latent state in the peripheral nervous system,, in sensory ganglia. The latent state is
characterized by an episomal viral genome, the production of latency-associated
transcripts (LATs), and the lack of infectious progeny virions (165). The host immune
system also contributes to the establishment of latency by suppressing infection and
limiting spread (13, 204). Inflammation and CD8+ T-cells have also been implicated in
maintaining HSV-1 in a latent state (37-38). Periodically, the latent HSV-1 is induced to
reactivate via “stress” stimuli including immune suppression, physical/emotional stress,
or exposure to ultraviolet (UV) light (164). Reactivated viral particles are then
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transported in an anterograde direction from the sensory neuron to the primary site of
infection resulting in asymptomatic shedding or recurrent infectious lesions at the
original infection site (105).

Clinical manifestation
HSV-1 infection is wide spread in the human population reaching 70-80%
prevalence in the adult population (222). The host first encounters the virus via contact
with secretions, skin, or mucosal membranes from symptomatic or asymptomatic
individuals shedding virus (218). Oral infection often results in the most frequent
manifestation of HSV-1 infection: herpes simplex labialis, the common cold sore (46).
Following primary oral infection, HSV-1 establishes latency in the trigeminal ganglia;
periodic “stress” stimuli result in reactivation and result in HSV-1 induced cold sores at
the initial site of infection in 20-40% of HSV-1 seropositive individuals (8). In immune
competent individuals, recurrent infection is less severe than primary infection and is
controlled within 1-10 days after initial onset of symptoms (152). HSV-1 is also
associated with genital herpes, herpetic stomatitis in the mouth, and cutaneous herpetic
infections like herpetic whitlow, eczema herpeticum, and herpes gladiatorum(8) . In
general, these infections are resolved in immune competent host and cause minimal long
term damage.
In contrast, HSV-1 infection may lead to serious infection of the eye and the CNS.
Infection of ocular tissue resulting in serious eye disease can happen via direct entry or
spread from non-ocular sites like the mouth (90). Ocular HSV-1 infection often initiates
severe immune reactions inducing blepharitis, conjunctivitis, retinitis, iridocyclitis,
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epithelial and stromal keratitis (8, 206). Herpetic stromal keratitis (HSK), a condition
that results in stromal damage, scarring, and loss of vision, is among the leading causes of
infectious blindness in developed countries (152). In addition to ocular disease, HSV-1
remains among the most common causes of viral encephalitis (92-93). Herpes simplex
encephalitis (HSE) is a rare, but life threatening consequence of infection of the nervous
system (209). Through recurrent infection in adults or maternal transmission to neonates,
HSV-1 infects the brain and causes acute inflammation and significant pathological
damage (92-93, 217). If untreated, HSE mediated damage leads to nearly 70% lethality
and few patients return to normal function (209).

Diagnosis, treatments, and vaccines
Diagnosis of HSV-1 infection is typically based on clinical histology and
presenting features, although various tests have been developed to confirm HSV-1
infection including changes in cytology, plaque assay, and serological methods (8).
However, detection of viral DNA by PCR is generally considered to be the most sensitive
measure for presence of HSV-1 (22). Therapy for HSV-1 infection ranges from no
treatment to a combination of antiviral drugs and corticosteroids (78, 179). The most
commonly utilized drug against HSV-1 is acyclovir, a nucleoside analogue (8).
Acyclovir is converted to its active form by viral thymidine kinase and incorporated into
viral DNA acting as a chain terminator and inhibiting viral replication (220). Acyclovir
also targets the viral DNA polymerase (ref). It can be given topically, orally, and
intravenously permitting it to treat a variety of HSV-1 infections including ocular,
genital, or HSE (8). Additional treatment utilizing corticosteroids to dampen the immune
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response to viral infection have also been explored, but the results remain unclear on its
efficacy or side-effects (78).
Research continues to develop new treatments for current HSV-1 infections and
preventative measures to impede future infection. While the majority of HSV-1 drugs are
nucleotide analogues that interfere with viral replication, several new categories of
antiviral drugs are being examined including helicase inhibitors, TLR agonist, and
therapeutic vaccines (220). In addition, work continues on development of a vaccine that
confers protection against HSV-1 infection. Both subunit based and live-attenuated
HSV-1 vaccines have been examined for efficacy in animal models and clinical trials
(96-97). Yet, none to date have been effective in protection (95, 220). Several factors
contribute to the difficulty in developing a HSV-1 vaccine, most notably opposition to the
use of a live-attenuated vaccine, and a failure of subunit vaccines to establish robust local
mucosal immunity (220).

Animal models
For HSV-1 research, a variety of animal models have been studied that mimic
human disease including rabbits and guinea pigs (72, 107, 151, 203, 218). However, the
mouse model of HSV-1 infection remains among the most common and practiced
methods for in vivo research (151). The outcome of HSV-1 infection in mice is highly
dependent on a variety of factors including virus and mouse strain, competence of the
immune system, and route of infection. For example, certain virus strains such as HSV-1
strain McKrae are more virulent in mice than other HSV-1 strains, though the exact
mechanism for the change in virulence is unclear (153). In addition, mouse strains like
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C57BL/6 are more resistant to HSV-1 challenge than Balb/C mice; these difference in
strains have been attributed to changes in the innate immune response (115). Mice
deficient in immune pathways have also been demonstrated to have increased
susceptibility or alternatively, enhanced resistance to viral infection (108, 116, 144). In
addition, the route of infection plays a major role in determining the pathogenesis of
HSV-1 in vivo. Together, these factors permit evaluation of several elements of HSV-1
infection. In these studies, two routes of in vivo HSV-1 infection are utilized: ocular
infection via corneal scarification and direct intracranial inoculation.
The ocular route of infection provides a physiologically relevant model for HSV1 infection in vivo (107). To mimic human disease, mouse eyes are scarified to permit
viral infection of the corneal stroma; stromal infection results in lytic infection at the
primary site of infection and HSV-1 can then enter the nerve termini that innervate that
region of the cornea (105). The virus is then transported in a retrograde manner, through
the axon to the trigeminal ganglia; HSV-1 replication in the trigeminal ganglia can be
measured as early as day 1 and peaks between day 3-6 post infection (218). HSV-1 can
continue to travel to the brain in a retrograde spread, or travel in an anterograde direction
leading to infection of the periocular skin, a measure of zosterform spread from the
trigeminal ganglia back to new peripheral tissues (14, 193). Viral titers in the cornea are
measured via eye swab while the trigeminal ganglia, brain, and periocular skin can all be
measured via plaque assay of harvested tissue homogenates.
In addition to examination of primary disease, the cornea model of infection also
permits evaluation of latency (218). The two primary measures of latency are
establishment and reactivation. Establishment refers to the presence of the HSV-1
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genome in the trigeminal ganglia in the absence of viral replication; by 28 days post
ocular infection, HSV-1 replication is no longer detectable and establishment is evaluated
by PCR for viral DNA (23, 201). Reactivation refers to the ability of the virus to shift
from latency to lytic infection and is typically measured by peripheral shedding of virus.
In vivo, mice have a very low rate of spontaneous reactivation compared to humans or
rabbits (141, 218); however, exposure to UV light in vivo or ex-vivo transplantation of
trigeminal ganglia permits measurement of viral reactivation (107, 184). In recent years,
examination of in situ hybridization in the trigeminal ganglia of latently infected mice has
revealed “rare neurons” that express high levels of lytic HSV-1 transcripts, viral DNA,
and protein (47). This low level of lytic antigen production absent infectious virus has
been termed molecular reactivation and likely contributes to the generation of immunity
during latency (47, 52, 94).
Both the ocular and the intracranial injection models evaluate the ability of HSV1 to invade and replicate within the CNS (42). Cornea infection results in trafficking of
the virus from the periphery into the brain and permits examination of neuroinvasiveness
(105). HSV-1 replication in the brain also provides a measure of viral fitness in the CNS;
however, several factors impact neuroinvasiveness including replication kinetics in
peripheral tissues, ability to be efficiently retrogradely transported, and actions of the
immune system. Neuroinvasiveness is highly virus and mouse strain dependent(12, 42,
117). To control for these external factors in peripheral tissues, HSV-1 infection via
direct intracranial inoculation permits evaluation of the virus’ ability to replicate within
the brain tissues (42). This CNS model of infection mimics human HSE and results in
high morbidity and mortality rates in vivo. Together, the ocular and intracranial
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inoculation routes provide in vivo mouse models for two important HSV-1 human
diseases.

The Immune Response to Virus
In response to viral infection, interferons induce signaling cascades that arm
immune defenses and provide the initial line of defense against invading pathogens and
malignant cells (77). The term interferon was originally derived from the ability of these
secreted factor to “interfere” with viral replication in host cells (77, 169). Divided into
type I and II categories, interferons initiate transcription of hundreds of genes through
binding their individual receptors (84, 155). The products of these interferon stimulated
genes have anti-viral, immune-modulatory, and cell regulatory functions which are
critical in the control of viral infection in vitro and in vivo(56, 84, 169). In the absence of
either the type I or type II interferon cascades, the host fails to mount effective immune
responses and becomes very susceptible to pathogen and tumor challenge (21, 73, 108,
129, 210). Therefore, interferons play a critical role in initiating the immune response to
viral challenge.
Type I interferon, also known as viral IFN, can be produced by nearly every cell
type within the host (169). Located together on chromosome 9 in humans or
chromosome 4 in mice, type I IFN genes are divided into several categories including
IFNβ, IFNα, IFN-w and IFN-t (155, 177). While the need for multiple types remains
unclear, each form of type I IFN shares structural homology that permits binding to the
single, common type I IFN receptor (155). The type I IFN receptor is composed of two
subunits, IFNAR1 & 2, which are associated with Janus activated kinase (JAK) 1 and
tyrosine kinase (TYK) 2 (34, 155). Upon binding of type I IFN, the IFNAR stimulates
12

auto-activation of JAK1 and TYK2 resulting in tyrosine phosphorylation of STAT1 and
STAT2. The phosphorylated STAT1 and STAT2 form heterodimers and in conjunction
with interferon regulatory factor nine (IRF9), become the IFN-stimulated gene factor 3
(ISGF- 3)(34, 155). This complex travels to the nucleus and binds IFN-stimulated
response elements (IRSE) in the DNA and initiate the type I IFN cascade.
In contrast to type I, type II IFN consists of a single form, IFNγ. Structurally
distinct from the type I IFNs, IFNγ is produced mainly by T-cells and natural killer cells
and targets immune cells including macrophages (77, 155, 169, 177). Upon binding
IFNγ, the two subunits of the type II receptors, IFNG1 and IFNG2, induce the
phosphorylation of STAT1 via JAK 1 and JAK 2 (155). The phosphorylated STAT1
forms a homodimer and translocates to the nucleus, binding to IFNγ activated sites
(GAS) elements upstream of target ISGs. This leads to the transcription of numerous
target genes and various outcomes that encompass the type II IFN cascade (77, 84, 169).
While both type I and type II IFN have been shown to be necessary in the control
of viral replication in vitro and in vivo (21, 73, 108, 129, 210), the recognition pathways
of the immune system, the focus of this thesis, primarily produce type I IFN in response
to viral challenge. Therefore, herein, the focus will be on the type I IFN system with
implicit acknowledgement of the importance of type II IFN in control of viral infection.

Interferon Stimulated Genes and Down Stream Effects.
While type I interferon has no reported enzymatic activity, the hundreds of
induced interferon stimulated genes (ISGs) mediate a variety of biological responses that
impact the ability of the virus to function and can elicit an anti-viral state within the cell
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(84, 155). Among the most prominent anti-viral ISGs is the dsRNA-activated
serine/threonine protein kinase, PKR. Upon binding double-stranded RNA, PKR is
activated and phosphorylates eIF2 leading to inhibition of protein translation (51, 169).
Several antiviral ISGs target other parts of the virus replication cycle, for example, 2’5’
oligoadenylate synthetase and RNase L target viral RNAs for degradation (84, 162). The
myxovirus-resistance proteins (Mx), IFN-inducible GTPases, were among the first
studied ISGs and have broad functions in both the nucleus and cytoplasm on multiple
types of viruses (77, 166, 169). ISG15, originally identified as a ubiquitin homologue,
protects against viral mediated degradation of immune components or modifies
enzymatic function to enhance the antiviral state (166). Yet, only a minor population of
ISGs have been fully evaluated in vitro or in vivo.
Type I IFN signaling is thought to induce or modify nearly 2000 genes. While
well over 300 have been identified to be highly induced via microarray studies, the
majority of these ISGs have been categorized as having no “direct” antiviral activity;
instead, they encompass a wide variety of functions that contribute to the antiviral state
(36). Type I IFN signaling has been shown to have immuno-modulatory and cell
regulatory functions (84, 169). Studies have demonstrated an increase in expression of
MHC class I and II, necessary components for antigen presentation to T-cells (36, 77,
166). Similarly, several ISGs encode chemokines and adhesion molecules critical for the
trafficking of lymphocytes to the area of infection (36). IFN signaling also leads to
increased expression of signaling molecules and transcription factors often involved in
the inflammatory response (36, 155). IFN has been shown to upregulate genes involved
in both protein degradation as well as apoptosis (10, 36). Numerous other ISGs have yet
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to even be categorized and fully evaluated. Together, in combination with the known
antiviral ISGs, IFN mediated effects result in host cells being rendered inhospitable to
virus infection.

IFN, ISG, and HSV-1 antagonism
Naturally, viruses have developed mechanisms to interfere with type I IFN and its
downstream effects (55, 84, 177). At any step within the type I IFN cascade, viruses can
block, sequester, or inhibit elements of the IFN signaling machinery. In addition,
successful viruses often antagonize the production or function of ISGs, most notably
PKR and RNaseL (84). HSV-1 is among the most adept viruses at subverting the
immune response; it encodes several viral proteins that delay and interfere with the type I
IFN cascade through known, and yet to be determined, mechanisms.
Among the best characterized mechanisms of viral antagonism of immunity is
HSV-1 neutralization of the PKR pathway. HSV-1 encodes a protein, ICP34.5,which has
been implicated in a variety of functions including inhibiting autophagy, processing
glycoproteins, and facilitating nuclear and cytoplasmic egress (16, 79, 146). Its most
prominent function, however, has been associated with interfering with host-protein
shutoff . ICP34.5 recruits protein phophatase 1a (PP1) and directs it to dephosphorylate
eIF-2, the target of activated PKR (60-61). The reduction in phosphorylated eIF-2
removes the PKR induced block and permits viral protein synthesis to continue
uninterrupted. In the absence of ICP34.5, HSV-1 is highly neuroattenuated in vivo with
restoration occurring only in PKR-/- mice (110). In addition to ICP34.5, HSV-1 encodes
a second PKR antagonist, US11. US11 acts by binding directly to PKR and preventing
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activation by dsRNA or PACT (40). A suppressor mutant lacking ICP34.5 had partial
restoration if US11 was under control of an immediate early promoter (25-26, 215).
Together, these data demonstrate that multiple HSV-1 proteins target PKR and
downstream pathways that contribute to the anti-viral state.
In addition to ICP34.5 and US11, the virus encodes several other known immune
antagonists. ICP0, an immediate early transactivator of HSV-1, interferes with several
aspects of the type I IFN cascade including STAT-1 signaling, with induction and
function of ISGs, and resistance to type I IFN signaling (43, 59, 135, 137-138, 187). The
virion host-shut off protein (vhs), a viral riboendonuclease, has also been implicated in
antagonizing the ISG antiviral response by degrading host transcripts, targeting type I
IFN receptors, and interfering with the activity of JAK/STAT pathway through activation
of the suppressor of cytokine signaling 3 (SOCS-3) (29, 226-227). In the absence of
either ICP0 or vhs, HSV-1 becomes very sensitive to type I IFN and the virus is
attenuated both in vitro and in vivo (113, 137). However, mutants lacking ICP0 or vhs
are partially restored in hosts lacking type I IFN signaling implying their action the type I
IFN cascade (108, 148, 150). In more recent work, ICP27, an immediate early viral
protein, has been identified in interfering with JAK/STAT signaling and the activity of
ISG15 (80-81).
These five viral proteins (ICP34.5, US11, ICP0, vhs, and ICP27) represent the
best characterized immune antagonists encoded by HSV-1. Yet, other viral proteins have
also been implicated in influencing the antiviral state including ICP47 and UL13 (19,
145, 183, 227). In addition, the virus has been found to counter several antiviral
processes including RNaseL and 2’5’ oligoadenylate activity, although no conclusive
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mechanism has been established. Together, the data demonstrate that HSV-1 employs
significant genetic capital in neutralizing type I IFN and its downstream cascade.

Pathogen Recognition Pathways
While type I IFN and its downstream effects have been examined for several
decades, recent research has focused on the pathways that induce the type I IFN cascade
(18, 67, 178). Over the past few years, the discovery of pattern-recognition receptors
(PRRs), adaptors, and signaling molecules has provided detailed mechanisms for the
recognition of a variety of invading pathogens. The host immune system relies on these
early recognition pathways to identify infection and induce the production of type I IFN,
specifically IFN. In the past few years, the area of pattern recognition has been divided
into two branches: the extracellular recognition pathway comprised of the toll-like
receptor family (TLR) and the intracellular recognition pathway represented by the Rig-I
like receptors (RLR) (18). Each family provides surveillance for specific areas within
the host cell environment and utilizes adaptors and signaling molecules to drive
production of IFN following infection.

Toll-Like Receptor Signaling
The toll-like receptor (TLR) family consists of several transmembrane receptors
that recognize pathogen-associated molecular patterns (PAMPs) (3). TLRs sample
extracellular contents surrounding host cells either through expression on the cell surface
or within endosomes. Originally discovered in Drosophila, 10 TLR genes are expressed
in mice and humans; each recognizes distinct PAMPs associated with bacteria, viruses, or
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fungi (3, 77, 86, 111). Together, these receptors play a key role in activating immune
cells inducing phagocytosis, cytokine secretion, and enhanced antigen presentation in
response to infection (77).
The majority of the TLRs most commonly associated with viral recognition bind
nucleic acid motifs within the endosome. TLR3 was among the first to be characterized
binding poly IC and double-stranded RNA (4). In a similar fashion, TLR9 was found to
recognize unmethylated DNA and both TLR7 and 8 bind to single-stranded RNA
elements (62-63). In addition to recognition via nucleic acid motifs, viruses have also
been described to activate TLR2 and TLR4 through recognition of viral proteins (65, 104,
235). Together, the data demonstrate that multiple TLR pathways are involved in the
recognition of viral pathogens.
With the exception of TLR3, each of the TLRs transmits its downstream signals
via myeloid differentiation primary response gene 88 (MYD88) (199). This adaptor is
recruited via its C-terminal Toll-IL-1 receptor (TIR) domain which interact with the TIR
domains found within the TLRs(20, 123). Upon stimulation, MYD88 recruits IL-1R
associated kinase (IRAK) via its N-terminal death domain (216); IRAK is then activated
by phosphorylation and in association with tumor necrosis factor receptor-associated
factor 6 (TRAF6), which leads to activation of JNK and NFκB pathways (20, 139).
MYD88 activation of IRF pathways has also been linked directly through TRAF6 (68,
87). In the absence of MYD88, the immune response to double stranded RNA,
unmethylated DNA, and single stranded RNA motifs are ablated demonstrating the
critical role for MYD88 in TLR signaling (4, 58, 62).
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The MYD88-independent pathway relies on the TIR domain containing adaptorinducing IFN (TRIF) for downstream signaling(175). In both TLR3 and TLR4 signaling,
TRIF acts as an adaptor facilitating activation of TBK-1 and subsequent activation of
IRF-3. While TLR3 exclusively uses the MYD88-independent pathway, TLR4 utilizes
both MYD88 dependent and independent pathways to stimulate the immune response to
infection (3, 66). Upon binding LPS or a viral ligand, TLR4 stimulates both MYD88
through interaction with MAL and TRIF through association with the TRIF related
adaptor molecule (TRAM) to activate pathways leading to NFκB and IRF-3 activation (3,
86, 199). Similarly, upon binding double stranded RNA, TLR3 activates TRIF pathways
leading to downstream signaling (175). In the absence of TRIF, the induction of IFNβ in
response to dsRNA or LPS is severely impaired, demonstrating the importance of TRIF
in inducing MYD88-independent response to virus infection (64).
The TLR family has been implicated in the recognition and immune response to
numerous viruses including HSV-1 both in vivo and in vitro. In the absence of TLR9,
plasmacytoid dendritic cells (pDCs) fail to induce type I IFN production in response to
HSV-1 challenge (100). HSV-1 glycoproteins have been identified in the activation of
the TLR2 pathway (7, 171). TLR3 has been shown to be important for protection
against herpes simplex encephalitis (HSE) in humans (24, 231). Yet, in contrast to other
viruses that encode multiple pathways to interfere with the TLR pathways, very few
HSV-1 processes have been identified to target TLRs. ICP0 has been implicated in
antagonizing TLR signaling through its interaction with USP7 (35). However, the
absence of TLR or MYD88 pathways has had minimal impact on HSV-1 replication; in
fact, the absence of several TLR pathways often resulted in reduced pathology in vivo
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(100, 102-103). Together, these results suggest that HSV-1 may be recognized via TLR
pathways, but it has minimal impact on infection. Thus, HSV-1 has devoted minimal
genetic capital to control this pathway.

Intracellular viral recognition pathways
Similar to the TLRs, the intracellular pathways of virus recognition utilize pattern
recognition receptors to recognize PAMPs within the cytoplasm. The Rig-I like receptor
family, comprised of retinoic acid inducible gene (RIG-I) and melanoma differentiation
associated gene 5 (MDA5) recognize elements of viral RNA within the cytosol (18, 54,
229). The closely related MDA-5 and RIG-I proteins contain two similar domains: A Nterminal caspase recruitment domain (CARD) and a C-terminal DExD/H box RNA
helicase (66). The C-terminal helicase has been demonstrated to confer RNA binding,
while the CARD domain is required for interaction with downstream adaptors (66).
Despite their similar domains, MDA-5 and RIG-I bind distinct RNA motifs resulting in
recognition of different subsets of viruses. MDA-5 binds longer molecules of viral
double stranded RNA and is required for recognition of positive-sense singles including
norovirus and picornaviruses (54, 120, 195) . In contrast, RIG-I detects single stranded
RNA sequences with a free 5’ triphosphate or short fragments of double stranded RNA,
each typically associated with negative-stranded RNA viruses (18, 83, 168). In the
absence of either RIG-I or MDA-5, mice are defective for the induction of type I IFN in
response to specific viral pathogens. These results demonstrate the critical role for the
RLR family in responding to viral challenge.
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In addition to the RLR family, additional intracellular pathways have been
implicated in the recognition of microbial DNA (18). While the pathways have not yet
been elucidated, several studies have demonstrated an IFN response to intracellular DNA
targets (74, 143, 192). The discovery of a DNA receptor, DNA-dependent activator of
IRFs (DAI), suggested a potential mechanism by which DNA recognition occurs (198).
However, further studies minimize the impact of DAI and suggest additional DNA
sensors are involved in the immune response (176, 214).

In contrast, another study

suggests that DNA recognition is mediated through RNA polymerase III conversion of
DNA to RNA; the newly formed RNA then activates RIG-I driving production of type I
IFN (1). Together, these data provide sufficient evidence to conclude that a DNA
sensing pathway exists and contributes to the induction of type I IFN in response to virus
infection.
Similar to the TLR pathways, the intracellular pathways are dependent on an
assortment of adaptors and signaling molecules. The primary adaptor for the RLR
family was independently identified by different four groups and given the following
names: IFNB promoter stimulator 1 (IPS-1), mitochondrial antiviral signaling (MAVS),
CARD adaptor inducing IFNB (Cardif), and virus induced signaling adaptor (VISA) (88,
133, 181, 224). For the purpose of simplicity, this molecule will be referred to as IPS-1.
IPS-1 contains an N-terminal CARD domain mediating interaction with the RIG-I and
MDA-5 (88). In addition, IPS-1 contains a C-terminal transmembrane domain that
targets itself to the outer mitochondrial membrane (181). Upon binding target RNA,
RIG-I and MDA-5 engage IPS1 resulting in recruitment of several signaling molecules
including TRAF2, TRAF6, Fas-associated protein with death domain (FADD), and
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receptor interacting protein 1 (RIP-1)(88, 224). These signaling molecules activate TBK
and in turn, lead to the activation of NFκB and IRF pathways, driving production of type
I IFN. In the absence of IPS-1, the host has a severe defect in RIG-I and MDA-5
signaling and is susceptible to a variety of RNA virus infections(101).
A second adaptor identified as part of the intracellular recognition machinery is
the stimulator of interferon genes (STING). STING, an endoplasmic reticulum
transmembrane protein, has been shown to interact with both IPS1 and RIG-I inducing
production of type I IFN (75, 194, 234). Further examination revealed that STING is
necessary for type I IFN production in response to intracellular DNA (76). In the absence
of STING, IFNβ production was ablated following challenge with non-CpG DNA;
STING also contributed to host defense against both RNA and DNA pathogens.
Together, the data demonstrate a critical role for both STING and IPS-1 in the
intracellular pathways leading to type I IFN production.
Despite their relatively recent discovery , many studies have revealed a variety of
viruses that target these receptors and adaptors (18). Through inhibition, cleavage, and
degradation, viral proteins interfere with the activity of the intracellular recognition
pathway and delay and inhibit type I IFN production (18, 50, 178). To date, no HSV-1
proteins have been directly implicated in antagonizing the RLR or DNA sensing
pathways. In fact, the mechanism for HSV-1 recognition is still not fully understood.
Several studies have demonstrated that HSV-1 induces a MYD88 independent production
of type I IFN (31, 158). Additional studies have implicated RIG-I, and STING as
possible components involved in identification(75, 160) . Yet, questions remain on the
exact pathways induced to produce type I IFN following HSV-1 infection.
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Initiation of type I IFN production
IFNβ is among the first type I IFN molecules produced and is critical in the type I
IFN signaling cascade (45, 202). Rapidly induced via pathogen recognition pathways,
IFNβ acts as an autocrine and paracrine activator of the type I IFN receptor, leading to
amplification of the type I IFN response (156). In the absence of IFNβ, IFNα subspecies
fail to compensate, resulting in increased host susceptibility to viral challenge (39, 169).
Together, the data demonstrate the importance of IFNβ to the immune response to viral
infection.
Regulation of IFNβ production occurs at the gene transcriptional level by
nucleosome obstruction of the transcriptional start site (2, 66, 114). Upon viral infection,
pathogen recognition pathways induce activation of factors that bind to IFNβ promoter
regions and facilitate nucleosome displacement from the IFNβ transcriptional start site
(114). The IFNβ promoter region contains four positive regulatory domains (PRDs): I,
II, III, and IV (66, 142, 147, 178). The PRDs bind to transcription factors that are either
present constitutively or induced by signaling via the type I IFN receptor. PRD I and III
bind members of the interferon regulatory factor (IRF) family, notably IRF-3 and IRF-7
(91). In contrast, PRD II and IV bind nuclear factor kB (NFκB) and AP-1 (a heterodimer
of activating transcription factor 2 with c-JUN). Following viral recognition, the
activated IRFs, NFκB, and AP-1 bind to the PRDs on the IFNβ promoter and recruit the
high mobility group protein, HMG-1 forming the IFN “enhancesome ” (91). The
enhancesome then recruits histone acetylation transferases (HATs) to aceylate lysine
residues of histone H3 and H4 in the nucleosome. Meanwhile, RNA polymerase II is
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recruited to the promoter and aceylation of the histone results in recruitment of a
nucleosome modification complex which displaces the nucleosome (2, 66, 114).
Displacement permits recruitment of TFIID to the IFNβ promoter and induction of IFNB
follows(2). Following production, IFNβ then acts in an autocrine and paracrine manner
initiating the type I IFN cascade in the infected as well as bystander cells (177). As the
infection continues, the levels of IFNβ plateau as other forms of type I IFN are produced
by infiltrating immune cells, most notably variants of IFNα by pDCs (9, 27).

IRF-3 & IRF-7
In recent years, interferon regulatory factor 3 and 7 have been identified as key
components of the early recognition response leading to the type I IFN cascade (18, 6667). IRF-3 is constitutively expressed and located in the cytoplasm of host cells in an
inactive form (66). Following stimulation via pathogen recognition pathways, the
transcription factor undergoes phosphorylation at a serine residue within its C-terminal
region (134, 180). Phosphorylation induces dimerization and formation of a homodimer,
or a heterodimer with activated IRF-7 (196). The dimer is then transported to the nucleus
where it binds co-activators CBP and p300 (112). This complex then targets the IFNβ
promoter at the PRD I and III sites and facilitates production of IFNβ (2).
In addition, several gene groups have been identified as partially or totally
dependent on IRF-3 for activation; these genes fall into two categories: genes dependent
on IRF-3 binding for expression and genes augmented by IRF-3 in the context of type I
IFN signaling (6, 44, 57). The IRF-3 augmented group includes several genes primarily
associated with the immune and interferon response including Rantes, ISG15, and ISG
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60 (6). In contrast, the IRF-3 dependent group includes genes from a variety of
categories including cell stress, apoptosis and proliferation, in addition to immune
response genes (6, 44). A subset of type I IFN, including IFNβ, IFNA4 and IFNa5, are
among the most notable IRF-3 dependent genes identified. In the absence of IRF-3, the
production of IFNβ is severely attenuated both in vitro and in vivo (67, 69). Together,
these data demonstrate the importance of IRF-3 in IFNβ production and initiation of the
type I IFN cascade.
In contrast to IRF-3, IRF-7 activity is highly dependent on type I IFN signaling.
IRF-7 is expressed at very low basal levels and has a short half life within the cell (174,
202). Upon type I IFN signaling, IRF-7 transcription is strongly induced via the ISGF3
transcriptional activating complex (173, 202). In an inactive form, IRF-7 resides in the
cytoplasm and is phosphorylated on its C-terminal regions upon stimulation by viral
infection (66). IRF-7 then forms a homodimer or heterodimer with IRF-3 and
translocates to the nucleus and activates production of additional type I IFN, primarily
subtypes of IFNα (173). Together, the data demonstrate a critical role for IRF-7 in the
type I IFN positive feedback look.
These findings led to a three step model of type I IFN induction (136, 174). First,
during the sensitization phase, viral infection is detected via pathogen recognition
pathways, leading to IRF-3 phosphorylation and dimerization (18). Activated IRF-3
translocates to the nucleus, forms the enchancesome, and drives expression of IFNβ (91,
136, 230). The released IFNβ initiates the second stage of the type I IFN response, the
inductive phase. IFNβ acts on both self and bystander cells leading to the expression of
IRF-7 via signaling through the type I IFN receptor (173). Viral activity continues to
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stimulate pathogen recognition pathways leading to IRF-7 activation. In turn, IRF-7
leads to further production of type I IFN and provides a positive feedback loop that drives
the type I IFN cascade. The continued type I IFN production initiates the final phase of
the IFN response, amplification. With production of numerous subset of type I IFN and
additional IFNAR receptors, the cell amplifies interferon stimulated genes resulting in
induction of a full-antiviral state (84, 169). Thus, IRF-3 was thought to govern the initial
induction of type I IFN and IRF-7 critical to subsequent stages.
However, in vitro and in vivo studies suggested a less IRF-3 dependent model for
type I IFN induction (69). Utilizing deficient mouse embryonic fibroblasts (MEFs),
IFNβ message was severely decreased in both IRF-3-/- and IRF-7-/- MEFs. In contrast,
IFNα message was normal in IRF-3-/- MEFs, but ablated IRF-7-/- MEFs following
challenge with EMCV, VSV, and HSV-1. In either case, the loss of these components
had no impact on endpoint viral replication (69). In vivo, intravenous challenge with
HSV-1 or EMCV resulted in complete lethality in IRF-7-/- mice compared to no change
in IRF-3-/- mice compared to control. Examination of serum revealed a deficit in IFNα
production in IRF-7-/- mice; no deficit was demonstrated in IRF-3-/- mice following
intravenous HSV-1 challenge.
These results led to a revised model that defined IRF-7 as the “master regulator”
of type I IFN and minimized the impact of IRF-3 (69). The new model proposes that
IRF-7, expressed at low basal levels, is activated by viral infection and forms either a
homodimer or heterodimer with IRF-3 driving production of type I IFN (173-174). In the
absence of IRF-3, IRF-7 expression is sustained by weak activation of ISGF3 through
spontaneously produced type I IFN (202).

Low level IRF-7 expression partially
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compensates for the loss of IRF-3, producing sufficient type I IFN to initiate the
interferon response. Later, infiltration of hematopoietic immune cells expressing IRF-7
constitutively produces sufficient type I IFN to control the infection in vivo (69, 106). In
contrast, the loss of IRF-7 results in initial IFNβ production via IRF-3, but no subsequent
amplification of the type I IFN response (69). The resulting deficit in type I IFN
production permits increased lethality in IRF-7 mice following intravenous viral
challenge. Together, the data suggest IRF-7 plays a critical role in control of HSV-1
infection; in contrast, IRF-3 has only a minimal impact during HSV-1 infection both in
vitro and in vivo.
However, data from several studies indicate the impacts of IRF-3 and IRF-7 on
HSV-1 replication may not be so clear. In the absence of IRF-3 or IRF-7, HSV-1
replication is unaffected compared to wild-type (WT) cells (69). One possible
explanation is that IRF-3 is specifically targeted by the virus to prevent induction of the
immune response. For example, in the absence of viral gene expression, UV-inactivated
HSV-1 induces IRF-3 activation and IFN induction to a higher levels than live virus,
implying manipulation of IRF-3 mediated recognition (31, 158). HSV-1 ICP0, a
multifunctional viral antagonist, has been shown to also interfere with IRF-3 activity via
its N-terminal RING finger domain, an E3 ubiquitin ligase (15, 113). Studies
demonstrated that HSV-1 prevents nuclear translocation of IRF-3 following co-infection
with Sendai virus in an ICP0 dependent manner(126). Similarly, ICP0 has been shown
to recruit IRF-3 and CBP/p300 to nuclear foci away from host chromatin, resulting in
reduced IFNβ production (128). In addition, HSV-1 vhs and ICP27 have also been
implicated in antagonizing the activity of IRF-3 (113, 125).
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Goals of the Thesis
In recent years, there has been increased interest in the pathways that induce type
I interferon in response to viral challenge. The discovery of RIG-I and the toll like
receptors initiated examination of the pathogen recognition pathways and led to the
discovery of new sensors, adaptors, and signaling molecules involved in type I IFN
induction. IRF-3 is central to these newly discovered pathways; it provides a critical
signaling component required for IFNβ induction and an efficient type I IFN response to
viral infection. In the absence of IRF-3, the pathogen recognition pathways would be
predicted to have delayed and deficient type I IFN production. The result would be
increased susceptibility to viral infection.
The first goal of this thesis was to fully evaluate the impact of IRF-3 dependent
pathways on HSV-1 replication in vitro. IRF-3 has been shown to play a critical role in
the type I IFN cascade initiated by the early pathogen recognition pathways. Therefore,
the loss of IRF-3 was predicted to impact the type I IFN response resulting in increased
viral replication in vitro. However, the loss of IRF-3 had been previously shown to have
no impact on viral replication in mouse embryonic fibroblast (MEFs), thus implying a
minimal role for IRF-3 in the IFN response to HSV-1. Yet, HSV-1 entry has been shown
to activate IRF-3 and the virus encodes viral proteins that antagonize IRF-3 activity;
together, these results suggest that IRF-3 does impact HSV-1 infection. In order to
address this apparent contradiction, immune cells lacking IRF-3 were challenged with
HSV-1 in vitro. Immune cells were predicted to have a more vigorous immune response
and the impact of IRF-3 on HSV-1 infection might be more discernable in these cell
types.
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The second goal of the thesis was to determine the role of IRF-3 on in vivo HSV-1
infection. IRF-3 had been previously shown to have no impact on survival following
intravenous infection with HSV-1. However, intravenous challenge likely bypasses the
physiologically relevant cell types for alphaherpesvirus infection: the epithelia and
neurons. Therefore, examination of the IRF-3 deficient mice via the ocular route of
infection permits evaluation of viral replication, trafficking of the virus, and the
establishment of latency in vivo. Intracranial challenge with HSV-1 permits examination
of lethality and viral fitness in the CNS.
The final goal of the thesis was to determine the pathways involved in recognition
of HSV-1. While IRF-3 signaling has been implicated in sensing HSV-1 infection in
vitro, the recognition pathway utilized by the host has not been identified. In order to
determine the pathways involved in HSV-1 recognition, immune cells and mice lacking
components of the RLR, TLR, and DNA sensing pathway were challenged with HSV-1.
The loss of one or more of these components would be predicted to have a significant
impact HSV-1 replication in vitro or in vivo.
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ABSTRACT
Type I Interferon (IFN) cascade is critical in controlling viral replication and
pathogenesis. Recognition pathways triggered by viral infection rapidly induce the type I
IFN cascade, often in an interferon regulatory factor 3 (IRF-3)-dependent fashion. This
dependence predicts that loss of IRF-3 would render early recognition pathways
inoperative and thereby impact virus replication, but this has not been observed
previously with HSV-1 in vitro. In this study, HSV-1 infected IRF-3-/- bone marrowderived dendritic cells (BMDCs) and macrophages (BMM) supported increased HSV-1
replication compared to control cells. In addition, IRF-3-deficient BMDCs exhibited
delayed type I IFN synthesis compared to control cells. However, while IFN pretreatment
of IRF-3-/- BMDCs resulted in reduced viral titers, a far greater reduction was seen
following IFN treatment of wild-type cells. This suggests that even in the presence of
exogenously supplied IFN, IRF-3-/- BMDCs are inherently defective in control of HSV-1
replication. Together, these results demonstrate a critical role for IRF-3 mediated
pathways in controlling HSV-1 replication in cells of the murine immune system.
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INTRODUCTION
Herpes simplex virus type I (HSV-1) is a ubiquitous human pathogen with high
seroprevalence in adults (51). HSV-1 is associated with numerous human diseases
ranging from the common cold sore in immune-competent individuals, to herpetic
encephalitis in neonatal and immunocompromised hosts. A member of the
Alphaherpesvirus family, HSV-1 exhibits two distinct phases of infection (49). Acute
infection typically occurs at peripheral epithelial sites and is characterized by lytic
infection and spread. In contrast, the virus shifts from lytic to latent infection in sensory
neurons which is characterized by limited gene expression and the persistence of viral
genomes in a transcriptionally active state. Following certain stimuli, periodic
reactivation of latency occurs, and may result in shedding of infectious virus at the initial
site of acute infection. Reactivation may also be associated with immunopathological
diseases, most notably ocular herpetic stromal keratitis.
A role for interferons (IFNs) in controlling viral replication is well-established. In
recent years, viral research has focused on cellular recognition of pathogen-associated
molecular patterns (PAMPs) and subsequent IFN induction, leading to the discovery of
toll-like receptors (TLRs) and retinoic acid inducible gene 1 (RIG-I) -like sensing
molecules (18). Such molecules respond to several virally-derived PAMPs. These include
MDA-5 and TLR-3 which recognize double-stranded RNA (13, 24), DAI and TLR-9
which recognize double-stranded DNA (14, 45), TLR-7 which recognizes singlestranded RNA (9), and RIG-I which recognizes triphosphate and double-stranded RNA
(16, 31, 53). Subsequent work identified the adaptor molecules necessary for antiviral
pathway signaling, including MyD88, TRIF and IPS-1 (19, 46, 52). Not surprisingly,
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numerous gene products from viruses such as HCV, WNV, influenza and vaccinia have
been identified to antagonize these pathways and serve to promote viral replication and
virulence by degradation, interference, or sequestration of early recognition components
(3, 11).
These newly-identified recognition pathways utilize IRF-3, IRF-7 and NFκB to
induce IFN transcription through cognate binding sites on the IFN-β promoter (38).
During initial induction of IFN, IRF-3 and NFκB, which are constitutively expressed,
become activated and translocate to the nucleus where they bind the IFN-β promoter to
form the IFN enhancesome (54). The initial IFN-β produced acts upon the IFNαβ
receptor (IFNAR) in both an autocrine and paracrine manner to up-regulate interferon
stimulated genes (ISGs), most notably IRF-7 (38). In concert with IRF-3, IRF-7
amplifies and facilitates expression of the full type I IFN cascade. In the absence of IRF3, IFN-β production is reduced but IFN-α levels remain normal, suggesting that IRF-7
activity can compensate for the loss of IRF-3 (15). In contrast, IRF-7 deficiency results
in significant reduction in serum IFN levels with a corresponding increase in
susceptibility to virus infection. IRF-7 was therefore dubbed “the master regulator” of
type I IFN-dependent immune responses (15). IRF-7-/- mice challenged with HSV-1
showed increased mortality compared to control and IRF-3-/- mice, but no increases in
viral titers were observed in IRF-3- or IRF-7-deficient cells in vitro (15). A possible
explanation for this lack of phenotype in vitro is that HSV-1 may control IRF-3 activation
so thoroughly that this pathway is neutralized during infection. UV-inactivated HSV-1
induces IRF-3 dimerization and activation, leading to IFN induction, suggesting that very
early events in infection are responsible for triggering this cascade in the absence of viral
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gene expression (6, 23). ICP0, an immediate early gene of HSV-1, interacts with IRF-3
and plays a critical role in preventing the induction of the IFN response (10, 23, 27, 28,
30, 42). Additional HSV genes such as the virion host shut-off protein, ICP34.5, and
ICP27 also interfere with the activity of IRF-3 (23, 26, 48). However, the increased
susceptibility of IFN receptor knockout mice to HSV-1 compared to wild type mice
suggests that despite so many genes regulating this pathway, the virus does not maintain
total control over the type I IFN cascade (22, 32). In addition, numerous recognition
molecules have been implicated in HSV-1 identification and the subsequent immune
response (for example TLR-3, TLR-2, TLR-9, RIG-I), but the loss of any of these
components does not result in any significant increase in viral replication in vitro (21, 35,
37, 55).
In these studies, we examined the impact of IRF-3 mediated pathways on HSV-1
replication using cells from IRF3-deficient (IRF-3-/-) mice. The absence of IRF-3 was
predicted to preclude the function of early recognition pathways and thereby impact
HSV-1 replication. No changes in HSV-1 replication in IRF-3-deficient mouse
embryonic fibroblasts (MEFs) had been observed previously, but we reasoned that
relative to MEFs, cells of the immune system might induce more vigorous IRF-3dependent antiviral responses, manifesting with a significant impact upon viral
replication. Using IRF-3 deficient bone marrow-derived dendritic cells (BMDCs) and
macrophages (BMM) we have demonstrated that IRF-3 mediated pathways are critical
for control of HSV-1 replication. Moreover, control of HSV-1 replication is dependent on
the type I IFN cascade in these cell types induced via IRF-3 mediated pathways.
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METHODS
Cells and viruses. Viral stocks were grown and titers were determined on Vero cells
(34). HSV-1 wild-type strain KOS was the background strain for this study (41).
BMDCs were generated from 6-8 week old C57BL/6 (Charles River Laboratories,
Willmington, MA) or 129S6 (Taconic, Germantown, NY) mice (25, 56). Briefly, bone
marrow was flushed from femurs of mice and cells were cultured as described below.
For generation of BMDCs, bone marrow was cultured in RPMI with 10% fetal calf
serum, Glutamax, Na pyruvate, non-essential amino acids, 250 U/ml penicillin, 250 U/ml
streptomycin, and 2% GM-CSF for 6-8 days at 37°C. BMDCs were then collected,
counted, and aliquoted for infection at several MOIs by the addition of virus in a minimal
volume of medium for 30 minutes at 37°C. Cells were then spun at low speed, inocula
removed, washed, resuspended, and plated in 35-mm wells for the duration of the
experiment. BMDCs were also generated from mice deficient in IRF-3-/- (15), IRF-7-/(15), STAT-1-/- (29) (Taconic, Germantown, NY), IFN-αβγ R-/- (AG129) (47).
Bone marrow macrophages were cultured as described (56). Briefly, bone marrow
was cultured in DMEM supplemented with 10% fetal calf serum, 5% heat-inactivated
horse serum, 20% L-929 conditioned medium, 250U/ml penicillin, 250U/ml streptomycin
for 7 days on non-tissue culture treated plates. At day 7, cells were washed with a 0.02%
EDTA solution, collected, and counted. The cells were plated in 35-mm wells and rested
for three days. The BMM were infected at MOIs of 0.01 and 1 by the addition of virus in
a minimal volume of medium for 30 minutes at 37°C, removal of inoculum, and followed
by the addition of complete medium.
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IFN-β ELISA. Bone marrow-derived dendritic cells were mock-treated or infected at an
MOI of 5 with HSV-1 and cultured in 1 ml of medium. Cultured supernatants were
harvested at 3, 6, 9, and 12 hours post infection and spun at low speeds to remove cells.
Supernatants were stored at -20°C before assay of IFN-β in the medium using 50 µl of
harvested medium in a mouse IFN-β enzyme-linked immunosorbent assay (ELISA) as
described in the kit protocol (PBL Biomedical Laboratories, Piscataway, NJ).
Antibody blockade. MAR1-5A3, an IgG1 monoclonal antibody specific to the IFN-α
receptor (Leinco Technologies, St. Louis, MO) was utilized as described (39). Briefly,
after infection, cells were plated in 1 ml of complete medium with 5μg/ml of MAR1-5A3
for the duration of the experiment. At specified times, cells were harvested and titered on
Vero cells under methylcellulose.
Mixing Experiment. BMDCs were collected, counted, and aliquoted for infection. WT
and IRF-3-/- BMDCs were mixed at a ratio of 1:1 such that cell numbers equaled those of
non-mixed controls. The mixed and non-mixed populations were then immediately
infected as previously described.
IFN-β pretreatment. BMDCs were treated for 16 hours with 100 U/ml mouse IFN-β
(PBL Biomedical Laboratories, Piscataway, NJ) or mock in PBS. BMDCs were then
collected, counted, and aliquoted for infection as previously described. No additional
IFN-β was added after infection.
Statistics. All statistical calculations were determined by Student’s t test and are relative
to control cells unless otherwise stated.
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RESULTS
Control of HSV-1 replication in BMDCs is IRF-3-dependent in vitro. A previous
study using IRF-3- and IRF-7-deficient MEFs demonstrated that the absence of either
signaling molecule did not significantly alter HSV-1 replication (15). Work performed in
this laboratory is in agreement with these previous observations (Fig. 2.1). Additional
experiments with IRF-3/IRF-7 double deficient MEFs also demonstrated no change in
HSV-1 replication (Fig. 2.2). BMDCs were chosen for infection in this study due to
their function as immune sentinels, their strong responses to IFN, and their critical role in
controlling HSV-1 infection in vivo (17, 43, 44). IRF-3-/- BMDCs yielded at least 10
times more HSV-1 replication than control cells at both 24 and 48 hours post infection at
each MOI tested (Fig. 2.3). In contrast, HSV-1-infected IRF-7-/- BMDCs did not yield
any increased viral titers compared to wild-type control BMDCs. These results suggested
that pathways for control of HSV-1 replication in BMDCs are dependent on IRF-3, but
independent of IRF-7.

BMM require IRF-3 for control of HSV-1 replication. Primary bone marrow
macrophages were infected in order to further assess the role of IRF-3 mediated pathways
in immune cells (2, 5). These adherent BMMs were also tested to exclude the possibility
that the replication pattern of HSV differed between MEFs and BMDCs because of their
adherence and non-adherence to plastic substrates in culture. The results, however,
demonstrated that the pattern of viral replication in the IRF-3-/- BMMs resembled that
seen in BMDCs, with increased viral yields as compared to control cells (Fig. 2.4). 10- to
100-fold increases in viral yields were demonstrated at both 24 and 48 hours post
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infection at MOIs of 0.01, 1, and 5 (data not shown). Interestingly, IRF-7-/- BMM also
supported increased viral replication. In contrast to BMDCs, IRF-7 deficient BMMs
permitted a 10- to 100-fold increase in viral replication compared to controls at 24 and 48
hours post infection. This increase in viral titers was greater in magnitude at the lower
MOI, but the impact of IRF-7 loss on HSV replication in BMMs was less than the impact
of loss of IRF-3. These data suggest a role for both IRF-3 and IRF-7 in control of HSV-1
replication in BMM. BMDCs, however, have no requirement for IRF-7 in controlling
HSV-1 replication, demonstrating difference in the innate immune response between
macrophages and dendritic cells. Overall, in both cell types, IRF-3 mediated pathways
are required to control HSV-1 replication in vitro.

BMDCs lacking interferon receptors permit increased viral replication in a STAT-1
dependent manner. Having identified a role for IRF-3 mediated pathways in controlling
HSV-1 replication in BMDCs and BMMs, focus was shifted to differentiating between 2
non-mutually exclusive mechanisms by which IRF-3 could be controlling HSV-1
replication. First, it is possible that IRF-3-/- BMDCs have delayed or reduced type I IFN
responses, disrupting the type I IFN cascade, and resulting in increased viral replication.
Second, it is possible that other IRF-3-dependent processes or gene products are directly
controlling HSV-1 replication. To address these possibilities, BMDCs lacking both Type
I and Type II IFN (αβ and γ receptors) were infected with HSV-1 (Fig. 2.5). These cells
lack IFN binding and signaling, but contain IRF-3, and thereby maintain elements of the
early recognition pathway via IRF-3 dependent gene expression. The IFN receptordeficient BMDCs permitted increased viral growth in a similar fashion to IRF-3-/-
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BMDCs and suggested that the type I IFN cascade was responsible for controlling HSV-1
replication (Fig. 2.4). Similar increases in viral replication were also seen in STAT-1-/BMDCs. Together, these data confirm that viral replication is significantly limited in
these cell types through IFN-driven STAT-1 signaling. While these data do not
completely exclude other IRF-3 dependent processes, the results strongly suggest that the
increased viral yields in IRF-3-/- BMDCs and BMMs are due to a delayed or defective
type I IFN cascade.

IRF-3 deficient BMDCs have a defect in IFN-β induction compared to WT control
cells. IFN-β plays a critical role in inducing an antiviral state and controlling viral
infection (18). A deficit or a delay in IFN-β induction would likely allow increased viral
replication, as seen in IRF-3-/- BMDCs. In order to examine this question, IFN-β protein
levels were determined by ELISA in control and IRF-3-/- BMDCs following infection
with HSV-1 (Fig. 2.6). BMDCs were infected at an MOI of 5 to ensure uniform infection
and minimize the contribution of bystander IFN. Even at this high MOI, IRF-3-/- BMDCs
yielded a statistically significant increase in HSV-1 titer at 12 and 24 hours post
infection. Examining IFN-β protein, IRF-3-/- BMDCs exhibited decreased and delayed
IFN-β production relative to wild-type control BMDCs. WT BMDCs produced
detectable levels of IFN-β as early as six hours post-infection and continued to escalate at
nine and twelve hours post infection. In contrast, IRF-3 deficient BMDCs only produced
measurable levels at twelve hours post-infection, suggesting a defect in the initiation of
IFN-β production. The IRF-3-/- BMDCs were, however, capable of producing IFN-β late
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in the experimental infection, thereby potentially allowing control of viral replication at
these later times.

IFNαR-blocking antibody augments viral growth in wild-type control and IRF-3deficient BMDCs. To demonstrate that production of type I IFN was a primary defect,
WT and IRF-3-/- BMDCs were infected and then treated with antibodies that block the
IFN-α receptor (IFNαR) or control IgG1 antibody (Fig. 2.7 and data not shown). We
postulated that if the restriction of HSV-1 replication in this system was dependent on
type I IFN induction then WT and IRF-3 deficient BMDCs should yield similar viral
titers in the presence of the blocking antibody. Control IgG1 had no impact on viral
replication in either cell type (data not shown). In contrast, the addition of IFNαR
blocking antibodies allowed both wild-type and IRF-3-/- BMDCs to produce higher
yields of HSV-1 such that viral growth curves for these two disparate cell types were
similar under these conditions (Fig. 2.7). It was also notable that untreated IRF-3-/BMDC cultures yielded similar titers as antibody-treated BMDCs at 24 hours post
infection. In contrast, by 48 hours post infection, antibody-treated IRF-3-/- BMDCs
yielded 10-fold more virus than untreated cultures. Together, these data demonstrate
that the type I IFN cascade is responsible for controlling HSV-1 replication in wild-type
BMDCs, and that at late time points, IRF-3-deficient BMDCs can exert partial type I
IFN- dependent control of HSV-1 replication.

IFN induction from wild-type BMDCs fails to restore control of HSV-1 replication
to IRF-3 deficient BMDCs in vitro. The preceding data suggested that IFN induction
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was defective in IRF-3 deficient BMDCs, but that these cells were still capable of
controlling viral infection once the type I IFN cascade had been initiated. The question
arose therefore, if the initial IFN induction and synthesis were restored, could IRF-3-/BMDCs limit HSV-1 replication to levels seen in wild-type control cells? We therefore
investigated whether bystander IFN, produced by WT cells, could restore control of viral
replication to IRF-3-/- BMDCs by mixing them in culture at a 1:1 ratio. The mixed cell
population was then infected with HSV-1 at an MOI of 0.01 and viral replication
measured (Fig. 2.8). Viral growth kinetics under these conditions were intermediate
between those observed in wild-type (low viral growth) and IRF-3-/- (high viral growth)
BMDCs. At 48 hours post infection, the mixed BMDC population gave a 10-fold
increase in viral yield over wild-type cells alone, and a 10-fold decrease in viral yield
over IRF-3-/- BMDCs alone. The results show that IRF-3-/- BMDCs are incapable of
controlling viral replication even in the presence of bystander IFN induced by viral
infection of WT cells. Another possibility, although less likely, is that the presence of
IRF-3-/- BMDCs resulted in a reduced total type I IFN concentration thereby permitting
increased replication in WT BMDCs. In either case, HSV-1 replication of IRF-3
deficient BMDCs was not limited in the context of bystander cell-produced IFN.

IRF-3 deficient BMDCs primed with IFN partially restore control of HSV-1
replication. The results from the cell mixing experiments suggested that IRF-3-/- BMDCs
were unable to respond fully to IFN production by WT cells. However, the ability to
generate a delayed IFN-β response coupled with the IFN-dependent decrease in viral
titers at late time points suggested that IRF-3-/- BMDCs were capable of inducing the type
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I IFN cascade, but with low efficiency. One possible model is that cells lacking IRF-3
are inherently slowed in their response to IFN, and need additional time to properly prime
in order to fully control HSV-1 replication in vitro. To test this, WT and IRF-3-/- BMDCs
were pretreated overnight with IFN-β, challenged with HSV-1, and viral yields measured
(Fig. 2.9). IFN pre-treatment of IRF-3-/- BMDCs significantly decreased HSV-1
replication as compared to untreated IRF-3-/- cells with a greater than 100-fold decrease in
viral titers at 48 hours post infection. Titers observed were comparable to those in
untreated WT control BMDCs. However, pretreatment of WT control cells resulted in
further decreases in viral replication, to levels at, or below, the level of detection. These
results together suggest that IRF-3 deficient BMDCs were capable of strongly responding
to IFN, but the overall immune response in controlling HSV-1 replication was still
defective compared to WT control cells.
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DISCUSSION
Despite mice or cells lacking IFN receptors being significantly more susceptible
to viral infection (22, 32), loss of IRF-3 and IRF-7 had surprisingly little impact on HSV1 replication in vitro (15). Several groups have suggested the lack of a growth phenotype
in IRF3-/- cells may be due to HSV-1 maintaining strict control over IRF-3-dependent
pathways through various viral genes including ICP0, ICP27, ICP34.5 and vhs, thereby
neutralizing the impact of IRF-3 mediated pathways (6, 10, 23, 26-28, 30, 35, 42). In this
study, we have demonstrated that HSV-1 replication was controlled in an IRF-3dependent manner in two types of immune cells. This control was dependent on type I
IFN and STAT-1 signaling with a primary defect in IFN production in IRF-3-/- cells.
Even in the presence of exogenously-supplied IFN, however, HSV-1 replication was only
partially controlled in IRF-3-/- BMDCs. Overall, the data presented provide evidence that
IRF-3 mediated pathways have a significant impact on HSV-1 replication in certain cell
types.
Previous studies examining HSV-1 and IRF-3-/- used highly permissive MEFs,
whereas in this study dendritic cells and macrophages were chosen. Given the roles of
dendritic cells and macrophages as sentinels of the immune system capable of controlling
viral infection in vivo, it is likely that these cells induced a more vigorous immune
response and were thereby less permissive to infection than MEFs (2, 5, 17, 43, 44). In
the case of HSV, a virus with multiple mechanisms to subvert IFN responses, loss of
IRF-3 can only manifest with increased viral titers in cells that respond strongly to IFN.
This idea is supported by studies with West Nile virus (WNV) (12). Only at late time
points, IRF-3-/- MEFs support nearly a 4 log increase in WNV titers compared to control
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cells suggesting robust IRF-3 dependent responses in control MEFs late in infection. In
contrast, examination of WNV in bone marrow macrophage cultures demonstrated
increased viral replication in IRF-3-/- BMM immediately, as early as 24 hours post
infection, and continued through 72 hours post infection (7). A similar difference in viral
replication between MEFs and immune cells was reported with mouse norovirus (MNV)
in the context of STAT-1 deficiency (50). These data support the hypothesis that immune
cells have a more vigorous antiviral response than MEFs and loss of IRF-3 on viral
replication may be more accurately measured in more restrictive immune cell types. This
hypothesis is especially relevant to HSV-1, which relative to WNV and MNV, has more
genes for IFN regulation, produces less dsRNA, and exhibits less sensitivity to type I
IFN.
Not surprisingly, in the absence of IRF-3, BMDCs and BMM were unable to
efficiently control HSV-1 replication (Figs. 2.3 and 2.4). While the IFN receptors are
intact in these cells, the early recognition signaling likely cannot proceed efficiently
without IRF-3, leading to a delay in the type I IFN cascade. Later, once secondary
rounds of infection have begun, alternate recognition pathways, most likely mediated
through IRF-7, can lead to the induction of type I IFN. This recognition by a secondary
pathway is supported by the observed late production of IFN-β (Fig. 2.6) and the
concomitant decreased viral replication in IRF-3-/- BMDCs at late time points (Fig. 2.7).
While IRF-3 is constitutively expressed in both BMDCs and BMM, basal expression of
IRF-7 varies according to cell type (33). Plasmacytoid dendritic cells (pDCs)
constitutively express IRF-7 while IRF-7 expression is reduced in conventional BMDCs
as compared to IRF-3. BMMs exhibited basal expression of both IRF-3 and IRF-7,
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potentially explaining increased replication in IRF-7-/- BMM but not in IRF-7-/- BMDCs
(8). Those studies observed a parallel trend in WNV replication in IRF-7-/- BMM and
BMDCs as seen here with HSV-1. Yet, in both cell types, the presence of IRF-7 cannot
compensate for the loss of IRF-3 mediated pathways. These results suggest that IRF-3
mediated pathways provide the major pathway of control of HSV-1 replication.
Together, our results demonstrate that the early recognition response through IRF3- mediated pathways controls HSV-1 replication in BMDCs and lead to the following
model (Fig. 2.10). Upon virus entry, an as-yet undetermined sensor recognizes HSV-1
and triggers a signaling cascade that activates IRF-3. IRF-3 activation leads to
production of IRF-3 dependent gene products, type I IFN, and an ensuing type I IFN
cascade, resulting in control of HSV-1 infection. In the absence of the type I IFN
cascade, achieved by knockout (Fig. 2.5) or receptor blockade (Fig. 2.7), BMDCs are
unable to control viral replication. Similarly, ablating IRF-3 and the early recognition
response results in increased viral replication due to delayed and reduced IFNβ
production (Fig 2.3, 2.4, 2.6). Exogenous IFN provided by bystander cells (Fig. 2.8) or
pretreatment (Fig. 2.9) partially restores control of HSV-1 replication in IRF-3-/deficient BMDCs, yet these cells remain defective in their control of HSV-1 replication
compared to treated WT cells.
Several non-mutually exclusive possibilities exist to explain this persistent defect
in the ability of IRF-3-/- BMDCs to control HSV-1 replication (Fig. 2.10, white squares).
One possibility is a defective autocrine and paracrine IFN amplification response. While
wild-type BMDCs quickly respond to IFN through STAT-1 and IRF-3 signaling
pathways, IRF-3-/- BMDCs can only respond through STAT-1-dependent, IRF-3-
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independent pathways. The absence of IRF-3 thereby severely decreases or ablates the
expression of several gene products, including IFN-β, IFNα4 and IFNα5 (1), resulting in
less robust IFN signaling. A second possibility is that IRF-3 dependent ISGs synergize
with Type I IFN receptor dependent ISGs and control HSV-1 replication, but fail to be
produced robustly in IRF-3-/- BMDCs. A third possibility is that virus recognition may be
required to augment the ongoing immune response. IFN primed IRF-3-/- BMDCs may
produce IFN effectors, but a lack of viral recognition signaling results in a delayed
effector response from ISGs. IRF-3-/- BMDCs may therefore require HSV-1 recognition
signaling through a secondary pathway before fully committing to a complete IFN
effector response, and this delay could result in the observed increased viral replication,
compared to wild-type controls.
Together, these data demonstrate that immune cells lacking IRF-3 are inherently
defective in the control of HSV infection. These data, however, conflict with previously
published in vivo data following intravenous (IV) infection (15). A possible explanation
is that following IV infection, IFN was being produced by plasmacytoid dendritic cells
(pDCs). pDCs, typically found in the lymph nodes away from the site of infection, are a
major producer of type I IFN, and they rely on TLR-9 and IRF-7 pathways to induce IFN
in response to HSV-1(4, 20, 40). Following IV infection, therefore, pDC production of
type I IFN likely overcomes the IFN deficit and thereby is able to control HSV-1
replication in the absence of IRF-3. Previous in vitro studies in MEFs suggested a role
for HSV-1 gene components in interfering with and neutralizing the activity of IRF-3 (10,
23, 26-28, 30, 36, 42, 48). In the cell types used in this study, heightened immune
responses likely reduced the efficacy of one or more viral immuno-regulatory
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components, or presented too great of a challenge for the viral activities to counter.
Therefore, the efficacy of HSV-1 genes in antagonism of IRF-3 likely depends on the
overall capacity of the infected cell to mount an immune response to the incoming virus.
Ongoing experiments in our laboratory seek to determine the precise molecules
responsible for HSV-1 recognition. As mentioned previously, several candidates in the
early recognition pathways have been implicated (21, 35, 37, 55) and cells lacking these
components are currently being tested for their ability to control viral replication in
BMDCs. Furthermore, in vivo studies in IRF-3 deficient animals are currently underway
in order to examine HSV-1 replication and pathogenesis in peripheral and neuronal
tissues.

64

ACKNOWLEDGEMENTS
This work was supported by NIH grants to David Leib (EY 09083) and the Department
of Ophthalmology and Visual Sciences (P30EY02687) from the National Eye Institute.
Vineet Menachery was also supported by Research Training Grant in the Visual Sciences
NIH T32 EY013360-09. Support from the Research to Prevent Blindness to the
Department, and a Senior Scientific Investigator Award to David A. Leib are gratefully
acknowledged. IRF-3-/-, IRF-7-/- mice were generously provided by T. Tanaguchi, and
AG129 mice by R. Zinkernagal. Special thanks to Marco Colonna and Steve McCartney
for provision of GM-CSF and helpful insight into BMDCs cultures. We also thank M.
Diamond for helpful feedback and provision of mice, and members of the Leib Lab for
helpful discussions.

65

Figure 2.1. In vitro replication in mouse embryonic fibroblasts. Primary MEFs were
infected with wild-type HSV-1 at an MOI of 1 or 0.01. At indicated times post infection,
cells and supernatants were harvested and viral titers assayed on Vero cells. Results
shown are mean titers of three independent experiments.

Figure 2.2. In vitro replication in double deficient mouse embryonic fibroblasts.
Primary MEFs lacking IRF-3 and IRF-7 were infected with wild-type HSV-1 at an MOI
of 5, 1, or 0.01. At indicated times post infection, cells and supernatants were harvested
and viral titers assayed on Vero cells. Results shown are mean titers of three independent
experiments.

Figure 2.3. In vitro replication in bone marrow derived dendritic cells. Primary
BMDCs were infected with wild-type HSV-1 at an MOI of 1 or 0.01. At indicated times
post infection, cells and supernatants were harvested and viral titers assayed on Vero
cells. Results shown are the mean titers of three independent experiments. *p value
<0.05 **p value <0.01.

Figure 2.4. In vitro replication in bone marrow derived macrophages. Primary BMM
were infected with wild-type HSV-1 at an MOI of 1 or 0.01. At indicated times post
infection, cells and supernatants were harvested and viral titers assayed on Vero cells.
Results shown are mean titers of four independent experiments. *p value <0.05 **p value
<0.01***p value<0.001.
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Figure 2.5. In vitro replication in BMDCs lacking IFN signaling. Primary BMDCs
derived from wild-type, IFNαβγ Receptor deficient (AG129) or STAT-1 deficient mice
were infected with wild-type HSV-1 at an MOI of 1 or 0.01. At indicated times post
infection, cells and supernatants were harvested and viral titers assayed on Vero cells.
Results shown are the mean titers of three independent experiments. *p value <0.05 **p
value <0.01***p value<0.001.

Figure 2.6. IFN-β secretion by infected BMDCs. Primary BMDCs were infected with
wild-type HSV-1 at an MOI of 5. At indicated times post infection, cells and
supernatants were harvested. Cells were removed by low speed centrifugation and
supernatants were assayed for IFN-β by ELISA. Results are shown in pg/mL and are
mean totals from three independent experiments. Cells and supernatants were also
assayed for viral titers at 6, 12, and 24 hours post infection and viral titers were assayed
on Vero cells. Results shown are the mean titers of three independent experiments. *p
value <0.05

Figure 2.7. IFNαR blockade in BMDCs. Primary BMDCs were infected with wildtype HSV-1 at an MOI of 0.01. Following infection, BMDCs were plated in media
containing 5μg/mL IFNαR blocking antibody (MAR1-5A3) for the duration of the
experiment. At indicated times post infection, cells and supernatants were harvested and
viral titers assayed on Vero cells. Results shown are the mean titers of three independent
experiments. *p value <0.05 **p value <0.01.
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Figure 2.8. In vitro replication following mixing BMDC populations. Primary WT
and IRF-3-/- BMDCs were mixed at a 1:1 ratio and infected at an MOI of 0.01. At
indicated times post infection, cells and supernatants were harvested and viral titers
assayed on Vero cells. Results shown are the mean titers of three independent
experiments. *p value <0.05.

Figure 2.9. In vitro replication following IFN-β pretreatment of BMDCs. Primary
WT and IRF-3-/- BMDCs were pretreated with 100U/mL mouse IFN-β for 16 hours.
Cells were then infected with WT HSV-1 at an MOI of 0.01. At indicated times post
infection, cells and supernatants were harvested and viral titers assayed on Vero cells.
Results shown are the mean titers of three independent experiments. *p value <0.05 **p
value <0.01.

Figure 2.10. Model for continued defect in IRF-3 deficient BMDCs. Post attachment,
HSV-1 infection is recognized through an unknown sensor mechanism that leads to
activation of IRF-3. The early recognition pathway mediates production of type I IFN
and IRF-3 dependent interferon stimulated genes leading to the control of HSV-1
replication via the type I IFN cascade. However, pretreatment with IFN does not restore
HSV-1 replication in IRF-3-/- BMDCs to WT levels. The continued defect is potentially
due to three, non-exclusive mechanisms outlined in white squares: defective IFN
amplification, defective antiviral trigger signaling, and IRF-3 dependent gene synergy
with the antiviral response. One or more of these mechanisms leads to continued defect
in the control of HSV-1 replication in IRF-3-/- BMDCs as compared to WT BMDCs after
IFN treatment.
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Figure 2.1. In vitro replication in mouse embryonic fibroblasts.
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Figure 2.2. In vitro replication in double deficient mouse embryonic fibroblasts.
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Figure 2.3. In vitro replication in bone marrow derived dendritic cells.
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Figure 2.4. In vitro replication in bone marrow derived macrophages.
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Figure 2.5. In vitro replication in BMDCs lacking IFN signaling.
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Figure 2.6. IFN-β secretion by infected BMDCs.
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Figure 2.7. IFNαR blockade in BMDCs.
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Figure 2.8. In vitro replication following mixing BMDC populations.
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Figure 2.9. In vitro replication following IFN-β pretreatment of BMDCs.
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Figure 2.10. Model for continued defect in IRF-3 deficient BMDCs.
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Chapter III
IRF-3 mediated control of HSV-1 replication in vivo.
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ABSTRACT
The initiation of the immune response at the cellular level relies on specific recognition
molecules to rapidly signal viral infection via interferon (IFN) regulatory factor-3 (IRF-3)
-dependent pathways. The absence of IRF-3 would be expected to render such pathways
inoperative and thereby significantly impact viral infection. Unexpectedly, previous
studies found no significant change in herpes simplex virus (HSV) pathogenesis in IRF-3/-

mice following intravenous HSV-1 challenge (Honda, K., et al., Nature 2005, 434:772-

777). In contrast, the present study demonstrated that IRF-3-/- mice are significantly more
susceptible to HSV infection via the corneal and intracranial routes. Increased viral
replication and inflammatory cytokine production were observed in brain tissues of IRF3-/- mice compared to control mice, with a concomitant deficit in production of both IFNβ
and IFNα. These data demonstrate a critical role for IRF-3 in control of central nervous
system infection following HSV-1 challenge. Furthermore, this work underscores the
necessity to evaluate multiple routes of infection and animal models in order to fully
determine the role of host resistance factors in pathogenesis.
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INTRODUCTION
Herpes simplex virus type I (HSV-1) is a ubiquitous pathogen of the alphaherpesvirus
family with high seroprevalence in the adult human population (64). Possessing two
distinct phases, HSV-1 causes a life-long infection with an initial lytic stage followed by
a shift to latency following trafficking to sensory neurons (63). Periodically, reactivation
from latency occurs and is associated with numerous diseases ranging from the common
cold-sore to ocular herpetic stromal keratitis (HSK), a leading cause of infectious
blindness (25, 47). Reactivation events as well as primary infections are associated with
herpes simplex encephalitis (HSE), a rare, but life threatening consequence of infection
of the central nervous system (CNS) (62). Through recurrent infection in adults or
maternal transmission to neonates, HSV-1 infects the brain and causes acute
inflammation and significant pathological damage resulting in nearly 70% lethality if
untreated (26, 62). In developed countries, HSV remains among the most common
causes of viral encephalitis(60).

Studies in mouse models and clinical studies have underscored the importance of the
immune response, especially type I IFN, in protection of the host from encephalitis (11,
15, 22, 68). In response to viral infection, type I IFN initiates a signaling cascade to
stimulate the immune system and provide a first line defense against invading pathogens
(50). Consisting of IFNβ and several forms of IFNα, type I IFN binds a receptor
(IFNAR) to induce an anti-viral state through production of numerous interferon
stimulated genes (ISGs) (19, 23, 53). In the absence of type I IFN signaling, mice are
very susceptible to disseminated peripheral HSV-1 infection, leading to increased viral
replication and increased mortality in vivo (28, 30, 45-46) .
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In the CNS, type I IFN plays a critical role in control of viral infections . While
peripheral tissues rely on plasmacytoid dendritic cells (pDCs) as the major IFN producing
cells, the brain is largely devoid of this cell type (1-2, 54). Instead, the CNS relies on
resident cells including neurons to produce and respond to type I IFN (10). In the
absence of type I IFN receptors, mice are very susceptible to encephalitis caused by a
variety of viral pathogens (9, 15, 22). Mice and humans with defects in type I IFN
signaling were also found to be more susceptible to HSE than control groups (13).
Together, these studies signal the importance of IFN signaling following CNS infection.
Recent studies, however, have focused on the importance of type I IFN induction in
limiting viral encephalitis. In particular, inborn disorders of IFN production, as well as
TLR-3 mutations, render otherwise healthy individuals susceptible to HSE (5, 68). These
data suggest that recognition pathways producing type I IFN in the CNS are as important
as IFN signaling in controlling virally induced encephalitis.

Work on pathogen-associated molecular patterns (PAMPs) has revealed two major
recognition pathways that lead to type I IFN production (3). The toll-like receptor (TLR)
pathways sample the extracellular milieu via receptors on the cell surface and within
endosomes (12, 18, 35). In contrast, the RIG-I like receptor (RLR) pathways utilize a
variety of sensors to recognize nucleic acid PAMPs within the cytosol of infected cells
(17, 58, 66). Each pathway utilizes a variety of adaptors and signaling molecules to
induce type I IFN production (24, 59, 65), yet both pathways converge onto three
common signaling molecules: IRF-3, IRF-7, and NFκB (52). Following activation via
the upstream recognition pathways, these signaling components bind the IFNβ promoter
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to form the “IFN enhancesome” (67). The IFNβ initially produced acts upon the IFNαβ
receptor (IFNAR) in both an autocrine and paracrine manner. This leads to the induction
of ISGs and the type I IFN cascade.

While NFκB is activated via independent adaptors, IRF-3 and IRF-7 were initially
thought to be interchangeable (52). The formation of IRF-3/IRF-7 homodimers or
heterodimers was necessary for binding specific regions of the IFNβ promoter and
production of type I IFN (19-20). Examination of cells and animals deficient in IRF-3 or
IRF-7, however, revealed distinct roles for the two signaling components. In the absence
of IRF-3, mice challenged with HSV-1 showed reduced serum IFNβ production, but
constant IFNα levels and the mice survived intravenous challenge (21). In contrast, IRF7 deficiency resulted in reduced serum IFNα levels and a corresponding increase in
mortality following HSV-1 intravenous infection. Therefore, IRF-7 was believed to
compensate for the loss of IRF-3 and dubbed “the master regulator” of type I IFN
dependent immune responses (21). Some recent studies, however, have indicated that the
respective impacts of IRF-3 and IRF-7 on HSV-1 replication may not be so clear cut. For
example, replication of HSV-1 in IRF-3- or IRF-7-deficient mouse fibroblasts was
unaffected relative to wild-type cells (21). One potential explanation postulated in
several studies is that IRF-3 is specifically targeted by the virus to prevent induction of
the immune response. For example, in the absence of viral gene expression, UVinactivated HSV-1 induces IRF-3 activation and IFN induction to a greater extent than
live virus (7, 29, 44). Viral genes including ICP0, virion host shutoff protein, ICP34.5,
and ICP27 have all been implicated in directly or indirectly targeting IRF-3 (14, 29, 37-
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39, 42-43, 56, 61). Together, these data suggest that the virus targets IRF-3 and implies
that IRF-3 can impact HSV-1 infection.

Recent studies from this laboratory demonstrated a significant increase in viral
replication in immune cells in the absence of IRF-3 (40). The loss of IRF-3 resulted in
increased viral replication in bone marrow-derived dendritic cells and macrophages due
to delayed and deficient type I IFN production. In the current study, the role of IRF-3 in
vivo was examined. Utilizing two routes of infection, via the cornea and through direct
intracranial inoculation, several aspects of HSV-1 infection were evaluated, including
viral replication, viral tropism, lethality, and cytokine production. The study confirmed
previous results showing no significant impact of IRF-3 on replication in peripheral
tissues (21). In contrast to previous studies, loss of IRF-3 had a significant impact on
viral replication, lethality, and cytokine production in the brain following both cornea and
intracranial routes of infection. Together, the results demonstrate that IRF-3 is a pivotal
determinant of viral tropism and determines the outcome of HSV infection of the central
nervous system.
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MATERIALS AND METHODS
Cells, virus, and mice. Vero cells were used for production and determination of viral
stock titers as previously described (49). The HSV-1 wild-type strains were strain 17
(HSV-1 17) and strain McKrae (HSV-1 McKrae) (36, 48). Mock-treated animals were
inoculated with uninfected Vero cell lysates prepared in parallel to viral stocks. The
mouse strains used were control C57B6 as WT mice and C57B6 IRF-3 deficient mice
(IRF-3-/-) (52) of either gender. Mice were housed in the Washington University School
of Medicine barrier facility and infected in the Washington University School of
Medicine biohazard facility. Mice were infected at between 6 and 8 weeks of age. Mice
were euthanized, if necessary, in accordance with Federal and University policies.

Animal infection procedures. For corneal infection, mice were anesthetized
intraperitoneally with ketamine (87mg/kg of body weight) and xylazine (13 mg/kg).
Corneas were bilaterally scarified with a 25G syringe needle, and virus was inoculated by
adding 2x106 PFU HSV-1 in a volume of 5µl. Mice were sacrificed at specified times
post infection for tissue harvest or observed daily for 21 days to evaluate survival.
For intracranial infections, mice were anesthetized as described above, and injected
intracranially with 100 PFU, 1x105 PFU of HSV 17 or mock in a volume of 20µl DMEM
using a Hamilton syringe with a 26G needle. Mice were sacrificed at specific times post
infection for tissue harvest or observed until day 21 post infection to evaluate survival.

Tissue titers. Following in vivo cornea infection, the following tissues were harvested
and tittered as previously described (49): corneal swabs, periocular skin, trigeminal
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ganglia, brain and brain stem. Briefly, tissues were harvested and stored at -80C until
processing. Tissues were mechanically disrupted, sonicated and tittered via standard
plaque assay on Vero cells.

Histological analysis. WT and IRF-3-/- mice were infected and harvested at day 3 and 5
post infection as described above. Briefly, mice were sacrificed and whole brains were
harvested into 4 ml of 10% formalin solution for fixation. The brains were then sectioned
sagittally and every tenth section stained using an anti-HSV-1 polyclonal antibody. Each
section was divided into five regions (olfactory bulb, central brain, mid-brain cerebellum,
and brain stem), and scored as either positive or negative for HSV antigen staining in a
masked fashion. Total positive regions were then divided by total sections counted to
obtain percent antigen positive regions.

Bead based cytokine analysis. Brains and brain stems were isolated and assayed
following in infection in vivo. A single brain or brain stem was harvested from mice and
mechanically disrupted in 1ml of phosphate buffered saline (PBS). Samples were then
sonicated on ice twice for 30 seconds and centrifuged for 4 minutes at 1500rpm at 4°C.
Supernatants were transferred to a 1.5mL eppendorf tube and centrifuged for 5 minutes at
7500rpm at 4°C. Supernatants were then transferred to new tube and diluted 1:1 with
serum sample diluent (Bioplex Mouse Serum Sample Kit, Bio-Rad, Hercules, CA). The
samples were then stored at -80°C until assayed. The Bio-Plex assay (Bio-Rad) was
preformed as described in the kit protocol. Briefly, equivalent amounts of protein, as
measured by Bradford assay, were added to each well of a multiplex mouse cytokine Bio91

Plex array. Cytokine concentrations were determined by comparison to a standard curve
provided by Bio-Rad and the results are reported as pg/ml/µg protein. The results shown
are the average from two experiments, with each experiment containing three or more
mice per data point.

IFN ELISA. Following a high-dose intracranial infection, brains were harvested at 12,
18, and 48 hours post infection. The brains were mechanically disrupted and sonicated
two times in 1ml PBS. Brain samples were then spun at 1.5K in a tabletop centrifuge.
The supernatant were then harvested and spun at 7.5K in a mini-centrifuge for 10
minutes. The clarified supernatants were harvested and stored at -80°C until processing
by ELISA. For both IFNβ and IFNα ELISA, 100µl of samples were assayed per kit
protocol (PBL InterferonSource, Piscataway, NJ). Protein levels were normalized via
Bradford assay and results were expressed pg IFN per mL per µg protein.

Real time RT-PCR of brain tissue. At the indicated time post-infection, brains were
harvested into 2mL of Solution D (4 M guanidine thiocyanate, 25 mL of sodium citrate,
0.5% sarcosyl, 0.1 M 2-mercaptoethanol) (6) and stored at -80oC. Total RNA was
harvested as previously described (45) and resuspended in a small volume of nucleasefree water. cDNA was generated using the iScript cDNA synthesis kit as per kit protocol
(Bio-Rad, Hercules, CA). PCR reactions were prepared with iQ SYBR green supermix
(Bio-Rad), 5% acetamide, primers (IDT, Coralville, IA) and 2

L cDNA. Each PCR

was performed in duplicate, and each infection condition was replicated in at least 4 mice
from 3 independent experiments. Actin primer sequences F92

5’:TGGTACGACCAGAGGCATACAG; R-5’:CCAACTGGGACGACATGGAG. IFNprimer sequences: F-5’:CAGCTCCAAGAAAGGACGAAC; R-5’:
GGCAGTGTAACTCTTCTGCAT.

Statistics. Statistical calculations were determined by Student’s t test and are relative to
WT control group unless otherwise stated herein. Statistical analysis of survival curves
utilized the log-rank test.
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RESULTS
IRF-3-/- mice have no defect in controlling HSV-1 infection following peripheral
cornea infection. Following infection with 2x106 PFU HSV-1 strain 17, examination of
corneal eye swabs from IRF-3-/- and WT mice demonstrated no significant increase in
viral replication following infection (Figure 3.1A.) Similarly, periocular skin from IRF3-/- mice had no major change in HSV-1 titers compared to control (Figure 3.1B); these
data suggest that IRF-3 plays only a minor role in HSV-1 control in the epithelial cells of
the cornea and periocular skin. Examination of the trigeminal ganglia also demonstrated
no significant increase in viral replication IRF-3-/- mice (Figure 3.1C). Additionally, no
change was observed in terms of lethality between IRF-3-/- and control; however,
previous reports have found HSV-1 17 to be less virulent in the C57B6 strain of mice and
no mice died in the experiments preformed here (33). Reactivation was also shown to be
similar between WT and IRF-3-/- suggesting that IRF-3 deficiency had minimal impact
one HSV-1 latency (Figure 3.2). Together, the data supported the previous findings by
Honda et al. and suggest that IRF-3 mediated pathways play only a minor role in
controlling HSV-1 during peripheral infection (21).

IRF-3-/- mice show increased mortality following cornea infection and an associated
increase in viral replication in the brain stem. As mentioned previously, HSV-1 strain
17 has minimal lethality and neuroinvasiveness in C57B6 mice following peripheral
challenge (33). To evaluate lethality and viral replication in the brain, a neurovirulent
and neuroinvasiveness strain of virus, HSV-1 McKrae, was utilized to determine
differences between WT and IRF-3-/- mice. As reported with HSV-1 strain 17, no change
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in viral titers was observed following HSV-1 McKrae infection in the cornea, the
periocular skin, or the trigeminal ganglia (Fig 3.3A-B, data not shown). However,
infection with the neurovirulent virus resulted in approximately 50% survival in wildtype mice and less than 10% survival in IRF3-/- mice, demonstrating significantly
(p<0.05) increased susceptibility of IRF3-/- mice (Fig. 3.4A). Evaluating viral titers, IRF3-/- brain stems were found to have a statistically significant increase in viral replication
as compared to wild-type controls following corneal challenge (Fig. 3.4B). Although the
differences were not statistically significant, whole brain titers from IRF-3-/- mice were
also increased compared to control (Fig. 3.4C). Together, these data suggest that IRF-3-/mice have a deficit in their ability to control lethal brain infection.

Loss of IRF-3 results in increased viral replication and increased mortality
following intracranial HSV-1 infection. The cornea model of HSV-1 infection mimics
the physiological course of eye disease seen in humans and permits evaluation of viral
replication in peripheral tissues. However, many factors can affect the ability of the virus
to replicate in peripheral tissues and also affect its ability to enter the brain and replicate
therein. Therefore, to evaluate the role of IRF-3 on HSV replication in the brain directly,
100 PFU HSV-1 strain 17 was inoculated into the cortex and the mice were evaluated for
mortality and viral replication. There was a significant increase in lethality of HSV in the
IRF-3-/- mice as compared to the controls (Fig 3.5A). While over 60% of the WT mice
survived IC injection, less than 20% of the IRF-3-/- mice survived the same challenge.
Correspondingly, beginning at day 3 and continuing at day 5, IRF-3-/- brains permitted a
10-100 fold increase in viral replication as compared to control mice (Fig. 3.5B). These
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results suggest that IRF-3-mediated pathways are important in controlling HSV-1
replication in brain tissues following direct intracranial injection.

IRF-3-/- mice had increased and altered antigen staining following IC challenge with
HSV-1. WT and IRF-3-/- mice were infected intracranially with 100 PFU HSV-1 strain
17 and harvested at day 3 and 5 post infection. Sagittal sections of the brain were stained
with an anti-HSV-1 polyclonal antibody. Sections were divided into five regions
(olfactory bulb, central brain, mid-brain cerebellum, and pons/medulla/brain stem), and
scored as either positive or negative for HSV antigen staining in a masked fashion.
Following scoring, total antigen positive regions were then divided by total sections
counted in order to calculate a percentage of antigen-positive regions (Table 1, Fig 3.6-7).
In general, IRF-3-/- mice displayed a higher percentage of antigen-positive regions than
WT mice. The central brain region (cerebral cortex, hippocampus, septum, thalamus,
and hypothalamus) was the site of inoculation and displayed a consistent and high
percentage of antigen-positive regions at both day 3 and 5 in both mice (Figure 3.6). In
contrast, the mid-brain, cerebellum, and brain stem displayed little antigen staining
(<10%) in either WT or IRF-3-/- mice at day 3 (Fig. 3.6A). By day 5, however, IRF-3-/mice displayed a significant increase in antigen positive sections as compared to controls
in midbrain, cerebellum and brain stem (Fig. 3.6A). In addition to increased antigen
positive regions, IRF-3-/- mice displayed a distinct antigen staining pattern compared to
WT mice as shown in representative images from the central brain. HSV staining of WT
lesions showed staining foci in cells with neuronal morphology (3.6B). In contrast, IRF3-/- brain sections had generalized antigen positive lesions with entire areas appearing
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uniformly stained with no apparent foci (Fig. 3.6C). This altered staining was consistent
in each IRF-3-/- antigen positive region examined and suggest increased antigen
production and spread in IRF-3-/- brains compared to control (Fig. 3.7). Together, the
increase in antigen production and distribution correlate with the previously observed
increased viral titers in IRF-3-/- brains (Fig. 3.4 & 3.5).

IRF-3-/- mice produce increased amounts of inflammatory cytokines following direct
intracranial infection. In addition to HSV-1 replication, several studies have implicated
inflammatory cytokines as contributing to increased lethality following CNS infection
(31-32). To assess inflammatory cytokine production in IRF-3-/- mice, total brain
homogenates were prepared and cytokines were assayed by a bead-based multiplex array
following IC infection with 100 PFU of HSV-1 strain 17 or mock treatment (Fig. 3.8). In
both the IRF-3-/- and WT brains, cytokine samples taken on day 3 were showed minimal
induction of cytokines with little or no variation between the virus-infected or mocktreated groups. At day 5, however, there was a significant increase in several
inflammatory cytokines in infected IRF-3-/- brains as compared to WT infected mice.
IRF-3-/- brains produced a 3.5 fold increase in IL-1β, a 4.6 fold increase in TNFα, and a
5.8 fold increase in IL-6 as compared to infected WT brains. This trend also extended to
IL-12 (7.1 fold), IL-10 (3.6 fold), as well as several chemokines including MCP-1,
Rantes, and MIP1β. In contrast, one cytokine (KC) demonstrated similar levels of
production in the WT and IRF-3-/- group. In addition, several were globally upregulated
(IL-5, IL-13, GM-CSF) in both WT and IRF-3-/- mice following virus- or mock-infection
suggesting that mechanical damage of injection was sufficient to induce their expression
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(Fig 3.8, data not shown). Together, the data suggest that in response to HSV-1 infection,
IRF-3-/- deficient mice produce a stronger inflammatory response as measured by
cytokine production. The timing of this increase in inflammatory cytokines, on day 5,
also coincided with the lethality seen in this model of infection.

IRF-3-/- mice have increased cytokine expression in the brain stem following
peripheral infection. Having shown increased cytokine expression in brains following
direct intracranial injection, it was of interest to observe changes in cytokine levels
following peripheral infection. Examination of the brain stem revealed increased
production for several cytokines in the IRF-3-/- mice as compared to control mice (Fig.
3.9). While maintaining similar levels at day 3, several cytokines had increased
expression at both days 5 and 7 in IRF-3-deficient mice. For example, there was
increased expression of IL-6, IL-12 and IFNγ at days 5 and 7 post infection. Other
cytokines had increased only at day 7 including IL-10, MCP-1, and G-CSF (data not
shown). The increased cytokine production at this late time corresponded with the peak
in lethality seen following corneal infection, consistent with inflammation being a cause
of increased mortality in IRF-3-/- mice.

IRF-3 deficient mice have a deficiency in type I IFN production. Previous work
demonstrated a deficit in the production of IFNβ following infection of IRF-3-/- bone
marrow-derived dendritic cells as compared to control cells (40). The current experiments
sought to determine whether IRF-3-deficient mice displayed a similar IFNβ production
deficit in brain tissues following IC infection. WT and IRF-3-/- mice were challenged with
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a high dose of HSV-1 and brains were harvested 12 and 18 hours post infection. At both
12 and 18 hours post infection there was a statistically significant difference in IFNβ
protein levels in IRF-3-/- mice as compared to WT control mice (Fig. 3.10A). At 12 hours
post infection, WT mice produce nearly 3.5 fold more IFNβ compared to IRF-3-/-, and 2.2
fold more IFNβ at 18 hours post infection. The 12 and 18 hour results therefore
recapitulated the results previously reported for BMDCs(40) and are consistent with the
observation that IRF-3-/- mice permit increased viral replication, and show increased
susceptibility to infection.

Previous studies in vivo showed no change in serum IFNα levels relative to control mice
following intravenous infection of IRF-3-/- mice with HSV-1 (21). The authors concluded
that IRF-7 was primarily responsible for IFNα production in vivo. To further assess that
idea in this work, brain samples were assayed by ELISA for IFNα (Fig. 3.10B). The data
showed a defect in IFNα production in IRF-3-/- mice as compared to WT control mice at
all time points tested. At 12 hours post infection, WT mice have nearly 5 fold more IFNα
than IRF-3- deficient brains which remained at minimal levels. However, by 18 hours,
IFNα production from IRF-3-/- brains was significantly above background levels
suggesting an IRF-3 independent response to viral challenge, consistent with a role for
IRF-7. While this IFNα production is still notably deficient compared to WT, it does
suggests that IRF-3-/- mice are capable of inducing the type I IFN cascade. Together, the
results confirm a deficit and delay in the induction of type I IFN in IRF-3-/- mice in vivo.
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The previous results demonstrated a significant difference between IRF-3-/- and WT mice
in terms of type I IFN production. However, those experiments required a higher dose of
HSV-1; attempts at a lower dose had failed to detect IFN within the linear range of the
ELISA assay. Therefore, following IC infection with 100 PFU of HSV-1, WT and IRF3-/- brains were removed, the olfactory bulb and brain stem discarded, and RNA harvested
from the remaining brain for analysis 18 hours post infection. The results demonstrated a
statistically significant decrease in fold expression of IFNβ RNA in IRF-3-/- mice as
compared to controls (Fig. 3.10C). The WT brains averaged a 3.4 fold increase in IFNβ
transcript as compared to mock samples; while in contrast, IRF-3-/- brains averaged a 1.9
fold increase. These results, coupled with the type I IFN ELISA results following high
dose infection, demonstrate a deficiency in type I IFN production in the brains of IRF-3-/mice.
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Discussion
The data in this study show that IRF-3 plays a critical role in the control of HSV-1 CNS
infection. While no impact of loss of IRF-3 was observed in peripheral tissues, its
absence significantly delayed and reduced type I IFN production in the brain. Therefore,
deficient IFN response most likely permitted HSV-1 to establish a foothold for infection,
resulting in increased viral replication and antigen staining in IRF-3-/- brains.
Concomitant with increased viral replication, the immune system induced an increased
inflammatory cytokine response in IRF-3-deficient mice and these factors combined to
result in significantly increased lethality. Together, these results highlight the importance
of the IRF-3 dependent immune response in preventing lethal CNS infection following
HSV-1 challenge.
Similar to previous reports in immune cells (40), IRF-3-/- deficient mice had
reduced type I IFN production in the brain following HSV-1 challenge, and delayed or
reduced type I IFN production has broad implications for susceptibility to viral
replication in the CNS. Deficient type I IFN production in brains contributes to
encephalitis in a variety of RNA virus infections including West Nile, Semliki virus, and
mouse hepatitis virus (8-9, 15, 22). The results also correspond with genetic studies in
humans demonstrating a deficiency in TLR signaling, specifically TLR-3, whose loss
results in increased susceptibility to HSE (5, 68). While TLR3 is dispensable for
protection of mice from viral infection, IRF-3 is apparently required for protection. IRF-3
is downstream of TLR-3 in the signaling pathway and these findings emphasize the
importance of this type I IFN induction pathway in controlling HSE in vivo (59).
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In addition to controlling viral replication, the inflammatory response to CNS
infection is also thought to contribute to lethality following HSV-1 challenge. Indeed,
the inflammatory response is both protective and harmful to the host during HSE.
Deletion or inhibition of parts of the inflammatory response result in the host succumbing
to HSV-1 infection (4, 34, 55). In contrast, antagonizing other inflammatory elements
has positive results in terms of morbidity and mortality (31-32, 41). In the absence of
type I IFN signaling, several viruses have been reported to induce increased CNS
inflammation in addition to increased viral replication (22, 57). A similar pattern
emerges in these studies, as IRF-3-/- mice have increased inflammatory cytokine
production in the brains following IC and cornea infection. The increase in inflammatory
cytokine production in IRF-3-/- mice preceded the major peak in lethality in both models.
These data suggest that increased inflammatory cytokine production, in addition to
increased viral replication, result in the increased mortality seen in IRF-3-/- mice.
Previous work with other viruses has suggested an alteration in viral distribution
or viral tropism in the context of defective or antagonized type I IFN signaling (16, 22,
51). In this study, assessment of viral antigen distribution revealed that while initially
limited to the central brain region, HSV-1 was distributed in the brain stem, cerebellum,
and mid-brain in both WT and IRF-3-/- mice by day 5 following IC infection. In each
region, IRF-3-/- brains exhibited a higher percentage of antigen positive regions, but the
overall location of the virus was similar between the WT and IRF-3-/- mice. There was,
however, a distinct antigen staining patterns in IRF-3-/- and WT brain sections. IRF-3-/mice showed lesions with uniform antigen positive regions while WT lesions showed
HSV-1 staining foci in cells with neuronal morphology. This observation is consistent
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with the hypothesis that IRF-3-/- mice permitting initial uncontrolled viral replication and
resulting in wide, uniform antigen staining.
The data presented in this study demonstrate a more complex role for IRF-3 than
previously shown (21). There is consistency between the previous study and the current
data examining replication in corneas, trigeminal ganglia, and periocular skin (data not
shown), but there are also some sharp distinctions when considering the current
observation of increased lethality and brain titers. A possible explanation is the nature of
the immune response in the CNS. In peripheral tissues, the type I IFN response is
primarily driven by plasmacytoid dendritic cells in an IRF-7 dependent manner; high
levels of IFNα are produced which can compensate for the loss of IRF-3 dependent
pathways (27). This model is supported by the previous intravenous challenge data (21)
and data in this study. In contrast, CNS tissues require local production of type I IFN to
control viral infection; serum IFN cannot compensate for an IRF-3 deficiency because
peripheral type I IFN fails to penetrate the blood brain barrier (10-11). Therefore, in the
brains of IRF-3-/- mice, HSV-1 can replicate uninhibited for several hours without
hindrance from type I IFN. Eventually, the type I IFN response is triggered through an
IRF-3 independent pathway, but by this time HSV-1 has established a foothold in the
CNS. This facilitates increased viral titers and inflammatory cytokine production in IRF3-/- mice and lead to encephalitis and a significant increase in lethality.
Taken together, these data demonstrate a critical role for IRF-3 in the brain
following HSV-1 challenge. The results also demonstrate a major delineation between
the peripheral and CNS innate immune responses. The data also underscore the
importance of testing multiple infection models, and measuring multiple parameters to
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fully ascertain the roles of host resistance factors in viral infection. Ongoing experiments
in our laboratory seek to evaluate changes in viral tropism and inflammatory infiltrates in
the brain of IRF-3-/- mice. Further experiments will determine the precise pathways and
molecules responsible for HSV-1 recognition. Several candidates involved in the early
recognition pathways have been implicated and cells and mice lacking these components
are being evaluated both in vitro and in vivo.
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Figure 3.1. IRF-3-/- mice have no change in peripheral tissues following infection
with HSV-1 17.

WT and IRF-3-/- mice were infected with 2x106 pfu HSV-1 17 per

eye. (A) Cornea swabs, (B) periocular skin, and (C) trigeminal ganglia were harvested
and titered at the specified days. The graphs represent the average of several mice at
each time point from two independent experiments.

Figure 3.2. Reactivation is not changed in IRF-3-/- mice as compared to control.
WT and IRF-3-/- mice were infected with 2x106 pfu HSV-1 17 per eye. Following
establishment of a latent infection, defined as 28 days post-infection, mice were
sacrificed and trigeminal ganglia (TGs) harvested. TGs were bisected and co-cultured on
a monolayer of Vero cells. Supernatants were removed daily for 7 days post-explant and
added to fresh Vero monolayers. This monolayer was then scored for cytopathic effect
and the results were recorded as the percentage of wells positive for reactivation.

Figure 3.3. IRF-3 plays a minimal role in peripheral tissues following corneal
infection with HSV-1 McKrae. WT and IRF-3-/- mice were infected with 2x106 pfu
HSV-1 McKrae per eye. (A) Cornea swabs and (B) trigeminal ganglia were harvested
and titered at the specified days. The graphs represent the average of several mice at
each time point from two independent experiments.

Figure 3.4, IRF-3-/- mice have increased lethality and increased viral replication in
brain tissues following HSV-1 McKrae cornea infection.. (A) Survival plot following
infection of WT and IRF-3-/- deficient mice with 2x106 pfu HSV-1 McKrae per eye.
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Survival experiments were conducted independently of the other experiments and
represent the sum of multiple experiments. (B) Brains and (C) brain stems were harvested
and titered at the specified days following infection of WT and IRF-3-/- deficient mice
with 2x106 pfu HSV-1 McKrae per eye. The graphs represent the average of several mice
from two independent experiments. The dotted line represents the limit of detection for
this assay. **p value <0.01.

Figure 3.5. IRF-3-/- mice have reduced survival and increased viral titers in the
brain following HSV-1 strain 17 intracranial infection.. (A) Survival plot of IRF3-/and WT mice following intracranial infection with 100 pfu HSV-1 17. Survival
experiments were conducted independent of the other experiments and represents the sum
of experiments. (B) Viral titers in whole brain tissue harvested at the specified days.
Data represents the average of several mice from two independent experiments. The
dotted line represents the limit of detection for this assay. *p value <0.05 **p value
<0.01.

Figure 3.6. IRF-3-/- brain sections have increased antigen stain following
intracranial HSV-1 infection. Following IC infection with 100 PFU HSV-1 strain 17,
brains were harvested on day 3 and day 5 post infection, formalin fixed, sectioned
sagittally, and stained with a polyclonal anti-HSV antibody. Sections were divided into
five regions (olfactory bulb, central brain, mid-brain cerebellum, and pons/medulla/brain
stem), and scored as either positive or negative for HSV antigen staining in a masked
fashion. Following scoring, total antigen positive regions were then divided by total
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sections counted in order to calculate a percentage of antigen-positive regions for day and
day 5 (A). B and C, representative immunoperoxidase stained (?) images from the central
brain region of WT and IRF-3-/- mice . *p value <0.05 **p value <0.01

Table 3.1. Summary of antigen scoring in IRF-3-/- and WT mice following IC
infection with HSV-1 or mock. Following IC infection with 100 PFU HSV-1 strain 17
or mock, brains were harvested on day 1, day 3, and day 5 post infection, formalin
fixed, sectioned sagittally, and stained with a polyclonal anti-HSV antibody. Sections
were divided into five regions (olfactory bulb, central brain, mid-brain cerebellum, and
pons/medulla/brain stem), and scored as either positive or negative for HSV antigen
staining in a masked fashion. Following scoring, total antigen positive regions were then
divided by total sections counted in order to calculate a percentage of antigen-positive
regions for each day and condition.

Figure 3.7. Representative brain sections from IRF-3-/- following HSV-1 infection
demonstrate altered antigen staining compared to control. Following IC infection
with 100PFU HSV-1 strain 17, brains were harvested on day 5, formalin fixed, sectioned
sagittally, and stained with a polyclonal anti-HSV antibody. Representative
immunoperoxidase stained images of mock, WT, and IRF-3-/- from the (A) (B) (C)
regions are shown.

Figure 3.8. IRF-3-/- mice show increased inflammatory cytokine production
following intracranial infection with HSV-1 strain 17. Following IC infection with
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100 PFU HSV-1 17, brains were harvested on days 3 and 5 post infection, processed, and
assayed via a bead based cytokine assay (BioPlex, Bio-Rad). The results shown are the
average 4-6 mice brain stems per group per time point. Statistical calculations based on
infected WT and infected IRF-3-/- mice. *p value <0.05.

Figure 3.9. IRF-3-/- mice show increased inflammatory cytokine production
following peripheral infection. Following IC infection with 100 PFU HSV-1 17, brains
were harvested on days 3 and 5 post infection, processed, and assayed via a bead based
cytokine assay (BioPlex, Bio-Rad). The results shown are the average 4-6 mice brain
stems per group per time point. *p value <0.05 **p value <0.01***p value<0.001.

Figure 3.10. IRF-3-/- mice have a deficit in type I IFN production following
intracranial infection with HSV-1. WT and IRF-3-/- deficient mice were infected with
1x106 pfu HSV-1 strain 17. Whole brain tissue was harvested as specified times,
processed, and analyzed for (A) IFNβ and (B) IFNα by ELISA (PBL Laboratories).
Results shown represent the average of 10-14 mice per group per time point from two
separate experiments. (C) Following infection with 100pfu HSV-1 strain 17, brain tissue,
excluding brain stem and olfactory bulb, were harvested for RNA 18 hours post infection.
Samples were assayed by real-time RT-PCR and are expressed as fold expression over
mock infected samples. Results shown are the average fold expression from 6-7 mice per
group per time point from two separate experiments. *p value <0.05 **p value
<0.01***p value<0.001.
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Figure 3.1. IRF-3-/- mice have no change in peripheral tissues following infection
with HSV-1 17.
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Figure 3.2. Reactivation is not changed in IRF-3-/- mice as compared to control.
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Figure 3.3. IRF-3 plays a minimal role in peripheral tissues following corneal
infection with HSV-1 McKrae.
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Figure 3.4, IRF-3-/- mice have increased lethality and increased viral replication in
brain tissues following HSV-1 McKrae cornea infection..
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Figure 3.5. IRF-3-/- mice have reduced survival and increased viral titers in the
brain following HSV-1 strain 17 intracranial infection.
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Figure 3.6. IRF-3-/- brain sections have increased antigen stain following
intracranial infection.
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Table 3.1, Summary of antigen scoring in IRF-3-/- and WT mice following IC
infection with HSV-1 or mock.

Sample
IRF-3-/Day 3
WT
Day 3
IRF-3-/Day 5
WT
Day 5
IRF-3-/Mock
WT
Mock

Olfactory
Bulb

Central
Brain

MidBrain

Cerebellum

Brain
Stem

Number
of Mice

2.6%

59.1%

0%

7.9%

8.3%

9

(1/39)

(26/44)

(0/42)

(3/38)

(3/36)

2.9%

53.5%

2.3%

0%

12.5%

1(35)

(23/43)

(1/43)

(0/38)

(5/40)

2.9%

67.3%

36.2%

29.8%

54.2%

(1/34)

(33/49)

(17/47)

(14/47)

(26/48)

7.3%

53.5%

15.6%

4.4%

33.3%

(2/41)

(24/45)

(7/45)

(2/45)

(14/42)

0%

6.3%

0%

0%

0%

(0/16)

(1/16)

(0/16)

(0/15)

(0/16)

0%

8.3%

0%

0%

0%

(0/9)

(1/12)

(0/12)

(0/12)

(0/12)
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8
9
9
4
3

Figure 3.7, Representative brain sections from IRF-3-/- following HSV-1 infection
demonstrate altered antigen staining compared to control.

Brain Stem

Cerebellum

Mock

WT

IRF3-/-
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Central Brain

Figure 3.8. IRF-3-/- mice show increased inflammatory cytokine production
following intracranial infection.
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Figure 3.9. IRF-3-/- mice show increased inflammatory cytokine production
following peripheral infection.
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Figure 3.10. IRF-3-/- mice have a deficit in type I IFN production following
intracranial infection with HSV-1.
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Summary, Implications, and Future Directions
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Summary of Research and Goals
The major goal of this research was to address the role of interferon regulatory
factor-3 (IRF-3) on herpes simplex virus type 1 (HSV-1) infection both in vitro and in
vivo. Prior to these studies, examination of IRF-3 in the context of HSV-1 infection had
led to contradictory results. Several studies argued that IRF-3 dependent pathways had
minimal impact on HSV-1 infection in vitro or in vivo (5, 14). In contrast, other studies
demonstrated that HSV-1encodes viral proteins that both directly and indirectly target
IRF-3 activity, implying a role for IRF-3 in the immune response to HSV-1 (12, 17, 2326, 31, 33). Therefore, the studies in this thesis sought to address the contradiction in
these data and clarify a role for IRF-3 in the control of HSV-1 infection.
While numerous studies have implicated the type I IFN response in control of
virus infection, the data presented here advocates a critical role for IRF-3 and the early
recognition pathways in initiating control of HSV-1 in vitro and in vivo. In the absence
of IRF-3, immune cells in vitro and brain tissues in vivo demonstrated a deficit in type I
IFN production following HSV-1 challenge. In each case, the IRF-3-/- cells and animals
eventually produced a type I IFN response; however, the delay and reduction in type I
IFN early during infection permitted an immediate increase in HSV-1 replication. Over
the course of infection, the small change in IFN production early during infection
manifested in enhanced viral replication leading to an increase in cytokine production.
These factors led to greater lethality for IRF-3-/- mice in vivo; therefore, the absence of
IRF-3 resulted in a significant shift in susceptibility.
However, contrasting major type I IFN cascade knockouts like STAT-1-/- and
IFNαγR-/-, IRF-3 deficiency resulted in no temporal shift in the survival curve, but only a
shift in total susceptibility. WT and IRF-3-/- mice died with the same kinetics after both
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ocular or intracranial HSV-1 infection; the major delineation was the total percentage of
dead. The data suggest that the loss of IRF-3 simply increased immediate HSV-1
replication creating an infectious dose that mimics a higher viral inoculation. The result
was increased lethality in IRF-3-/- mice, but in both mice, the likely mechanisms causing
death were a combination of viral replication and subsequent inflammation in the CNS.
While the loss of IRF-3 does not ablate a type I IFN response, the delay in induction
results in an early increase in HSV-1 replication which has major impact on the course
and outcome of infection. Overall, the loss of IRF-3 demonstrates the importance of the
early recognition pathways on a timely immune response to viral challenge.
From in vitro studies, the necessity of IRF-3 appears to be cell-type dependent. In
MEFs, the loss of IRF-3 has minimal impact on HSV-1 replication (14). In contrast,
bone marrow derived dendritic cells and macrophages yield increased HSV-1 titers in the
absence of IRF-3. One explanation implicates the differing responses to virus infection
in these cell types. Immune cells like BMDCs and BMM are expected to have a vigorous
immune response to viral challenge, producing and responding to type I IFN production.
In contrast, while MEFs respond to type I IFN stimulation, the cells are unable to
completely control HSV-1 replication even with IFN pretreatment. In addition, loss of
critical components of the IFN response including STAT-1 or IFNαR has only modest
impact on HSV-1 replication in MEFs. These data suggest that either an insufficient
immune response, HSV-1 antagonism, or a combination of both result in reduced efficacy
of type I IFN in MEFs. In immune cells, the opposite may be true with a sufficient
immune response resulting in less effective HSV-1 antagonism. The loss of IRF-3 in this
situation results in increased HSV-1 replication in these cell types. Together, the data

130

demonstrate the importance of cell type selection to in vitro experiments. While MEFs
represent a standard cell type, their use in examination of the immune system may be
inadequate. At a minimum, immune cells like BMDCs and BMM should be used in
addition to MEFs in characterization of immune functions.
In vivo, the necessity of IRF-3 appeared to be CNS specific. Loss of IRF-3 in
peripheral tissues has minimal impact on viral replication following HSV-1 challenge.
However, in the brain, IRF-3 deficiency resulted in enhanced viral replication and
greater inflammatory cytokine titers which likely account for increased lethality seen in
IRF-3-/- mice. Examination of type I IFN production revealed a deficit in IRF-3-/- brains
as compared to controls, providing a mechanism for increased HSV-1 replication and
suggesting a CNS specific necessity for IRF-3. While peripheral tissues primarily utilize
type I IFN production by plasmacytoid dendritic cells (pDCs), the brain is largely devoid
of this cell type (1-2, 30). Instead, the CNS relies on resident cells to produce and
respond to type I IFN (9). In the absence of IRF-3, the CNS fails to produce an
immediate type I IFN response and HSV-1 establishes a foothold for infection.
Augmented viral replication follows which leads to increased cytokine production and
increased lethality. In the periphery, the loss of IRF-3 impacts local production of type I
IFN as demonstrated by reduced IFNβ (14, 29). However, infiltration by immune cells
and IRF-7 mediated production of IFNα likely rescues the type I IFN cascade and
prevents the virus from establishing a foothold in peripheral tissues. This exogenous IFN
production by infiltrating cells is not available in the CNS as few pDCs are found in the
brain and type I IFN has not been shown to pass through the blood brain barrier (9-10).
Therefore, the CNS requires local production of type I IFN and IRF-3 is critical for a
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timely and efficient response. In the absence of IRF-3, the virus gains its foothold and
the result is increased susceptibility to HSV-1 CNS infection.

Implication of Thesis
Several studies have demonstrated the importance of type I IFN in limiting viral
infection in the periphery and the CNS. In the absence of IFNα/γR or IFN signaling,
mice become very susceptible to infection caused by a variety of viruses including HSV1 (6, 8, 13, 15-16, 19). In this study, the loss of IRF-3 also renders mice more susceptible
to HSV-1 infection and lethality, but only in the context of CNS infection. The results
contrast reports from West Nile virus (WNV) infection of IRF-3-/- mice. Deficiency in
IRF-3 results in increased WNV replication in peripheral tissues, altered tissue tropism,
and earlier entry into the CNS (6). This data demonstrate that in the context of WNV
infection, IRF-3 is an essential regulator in both peripheral and CNS tissues. However,
the loss of IRF-3 has no detectable impact on HSV-1 replication in the periphery.
One possible explanation is increased sensitivity of HSV-1 to type I IFN as
compared to WNV. In the periphery, the loss of IRF-3-/- has been shown to delay, but not
significantly diminish systemic accumulation of type I IFN in response to WNV or HSV1 infection (6, 14). The delay in type I production potentially permits a small, immediate
increase in viral replication in both virus types. However, the eventual type I IFN
response in the periphery serves to limit HSV-1 infection and spread. In contrast, WNV
is relatively resistant to type I IFN and capitalizes on the initial delay with increased viral
replication. Another possible explanation involves cell-type tropism; WNV infects a
wider range of cells during its normal course of infection and thus requires the ability to
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modulate the immune response in a variety of cell types. In contrast, HSV-1 primarily
infects epithelial cells and neuronal cell types during physiologically infections; it
bypasses the need to infect and control immune cells by transport via neuronal axons.
Therefore, HSV-1 may not have developed methods to antagonize the immune response
in these cell types.
Immune cells, including BMDCs and BMM, require IRF-3 dependent pathways
to limit HSV-1 replication. In the absence of IRF-3, both BMDCs and BMMs are unable
to control HSV-1 replication until type I IFN is produced via an alternate pathway. This
results in control of HSV-1 infection once the type I IFN response is initiated in the
periphery in vivo. This hypothesis is supported by studies of STAT-1-/- and IFNαβγR-/mice. Loss of type I and type II IFN receptors results in multi-organ failure and systemic
infection following HSV-1 challenge (19). In contrast, STAT-1-/- mice control peripheral
viral replication, but succumb to CNS infection following HSV-1 infection. A major
distinction between these mice was the ability to produce and respond to type I IFN via
the type I IFN receptor (unpublished, Pasieka et al). Antibody blockade of IFNαR
resulted in systemic infection and organ failure in STAT-1-/- mice. Together, the data
from the IRF-3-/- and STAT-1-/- mice demonstrate that systemic HSV-1 infection is
severely limited by even an attenuated type I IFN response in the periphery.
In contrast to the periphery, the data demonstrates that IRF-3 dependent pathways
are critical in limiting viral replication and lethality following infection of the CNS. In
both HSV-1 and WNV, the loss of IRF-3 results in increased HSV-1 replication in the
CNS tissues following direct and peripheral infection (6). These data correlate with
observations in humans regarding the role of TLR pathways in herpes simplex
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encephalitis (HSE). Inborn disorders of type I IFN production have been demonstrated to
render healthy individuals susceptible to HSE, most notably mutation in TLR-3 (3, 35).
In addition, TLR-3 deficiency resulted in enhanced WNV replication in neurons in vitro;
in vivo, TLR-3-/- mice have greater WNV replication in the CNS and increased lethality
(7).

While TLR3 is dispensable for protection from HSV-1 infection in mice (35), the

loss of its downstream signaling molecule, IRF-3, rendered mice susceptible to CNS
infection in the current study. Together, these data demonstrate the importance of early
recognition sensors and IRF-3 dependent pathways in the control of viral infection of the
CNS. By initiating a timely type I IFN response, IRF-3 dependent pathways limit initial
CNS viral replication; in their absence, viruses like HSV-1 can establish a more robust
CNS infection that can lead to death. Therefore, studies examining modulation and
disruption of the IRF-3 dependent pathways must continue. Recent work utilizing high
throughput screening of a pharmacologically active compound library has revealed
several antipsychotic drugs to be direct inhibitors of innate signaling pathways (36).
Patients receiving these drugs might be more susceptible to HSE, similar to what has
been reported in genetic studies for TLR-3 deficiency.
The results from HSV-1 and WNV infection also suggest a neuroprotective role
for IRF-3 either through induction of type I IFN or an IRF-3 dependent cascade. A
recent study demonstrated that viral infection is not a requirement for protection provided
by IRF-3 in the brain. Preconditioning of the mouse brain with lipopolysaccharide (LPS)
protected the mouse from ischemic injury following cerebral artery occlusion; this
protection was found to be dependent on type I IFN production via IRF-3 dependent
pathways (22). Together, the data suggest that IRF-3 may be a suitable therapeutic target
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for IFN induction in the brain. Direct treatment within type I IFN has been utilized in a
variety of human illnesses including hepatitis virus infection, multiple sclerosis and
gliomas (4, 11, 32). However, several major problems have been identified in utilizing
IFN treatment, most notably a short half life in vivo and inaccessibility to the CNS (27).
In addition, IFN treatment has been associated with numerous clinical side effects
including depression and brain toxicity (27) . By targeting IRF-3 in the brain, treatment
may lead to physiological appropriate amounts of IFN being produced in the CNS by
local cells; the result may be increased half-life for IFN in targeted tissues, lowered
toxicity, and decreased side effects. Targeting IRF-3 might also be used as a
prophylactic treatment to prevent viral encephalitis if a person is known to be infected
with or exposed to HSV-1 or another neurotropic virus. Whereas a delay in type I IFN
induction result in augmented viral replication the CNS, early induction and priming via
IRF-3 might limit infection. A recent study has identified a chemotherapeutic agent, 5,6dimethyl-xanthenone-4-acetic acid (DMXAA), as a potent and specific activator of IRF-3
(28). Through a yet undetermined mechanism, DMXAA activates IRF-3 pathways in an
IPS-1 and MYD88 independent manner and, unlike LPS, fails to induce TNFa
expression. Together, DMXAA and other drugs that target IRF-3 may prove to be an
effective therapeutic in treatment of viral infection of the CNS.
In addition to the necessity of IRF-3 in the CNS, these in vivo experiments
illustrate the importance of inspecting several routes of infection. The initial studies
examined HSV-1 infection following intravenous inoculation (14). In such infections,
the virus would be expected to be shuttled to the liver or spleen, each sites with
considerable immune cell populations. The results demonstrated that in such an
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experiment, IRF-3 had minimal impact whereas IRF-7 deficient mice had significant
lethality in vivo (14). However, this method bypasses the tissues associated with
physiological HSV-1 infections: the epithelia and neuronal cell. In this study,
examination of the ocular route of infection permitted evaluation of the full HSV-1
lifecycle. While replication was unaffected in the epithelial tissues and the sensory
ganglia, the brain demonstrated increased susceptibility. Intravenous infection likely
provides minimal exposure to brain tissue and thus underestimated the role of IRF-3 in
limiting HSV-1 infection. For the same reason, in addition to peripheral infection,
intracranial injection has been utilized to explore HSV-1 infection of the CNS.
Numerous factors influence the ability of the virus to enter the CNS following peripheral
infection; therefore, to adequately evaluate neurovirulence versus neuroinvasiveness,
direct injection of the virus into the brain is required. In each case, the differing routes
of infection answered different in vivo questions. Intravenous infection examines the
immune response to a systemic infection. Ocular challenge examines physiologically
relevant portions of HSV-1 infection cycle and intracranial injection evaluates
neurovirulence and fitness in the brain. Reliance on a single route or model of infection,
however, fails to adequately evaluate the immune components being studied.

Future Directions
An immediate area of interest involves further characterization of HSV-1
infection in IRF-3-/- brains. The presented data demonstrates increased viral replication
due to a deficit in type I IFN production in IRF-3-/- mice. In combination with
inflammation, increased viral replication leads to increased lethality in IRF-3-/- mice as
compared to controls following HSV-1 challenge. Interestingly, while increased antigen
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production and distribution was observed in IRF-3-/- brain sections, the staining pattern
was also distinct compared to WT mice. As mentioned previously, HSV-1 staining in
IRF-3-/- brain sections had generalized antigen positive lesions contrasting focal staining
found in WT brains. One possible explanation suggests that the absence of IRF-3 simply
results in increased antigen production in the infected brain regions. An alternative
explanation suggests a possible shift in tropism with HSV-1 infection of support cells in
addition to neurons. While some HSV-1 infection of support cells like astrocytes and
glial cell have been reported, neurons are typically the target of HSV-1 infection (20-21,
34). Utilizing dual fluorescence staining, changes in viral tropism in IRF-3-/- can be
determined with specific markers for neurons, astrocytes, microglia, and other cell types
found within the brain. Further examination these cell types in vitro may also reveal a
shift in susceptibility in the absence of IRF-3, similar to BMDC and BMM. Initial
examination of cortical neurons demonstrated no change in HSV-1 replication in IRF-3-/cultures as compared to controls (Fig 4.1A); however, primary IRF-3-/- astrocyte cultures
demonstrated increased viral replication in initial experiments (4.1B).
A second area of interest involves the continued defect of IRF-3-/- BMDCs in
controlling HSV-1 replication following IFN pretreatment. One possibility is that
defective autocrine/paracrine IFN amplification or the loss of specific ISGs result in the
failure to restore complete control of viral replication in IRF-3-/- BMDCs. An alternate
hypothesis is that the virus recognition machinery may be required to augment the
ongoing immune response. In the absence of type I IFN signaling, BMDCs fail to
mature following antigenic stimulations (18). In these studies, IRF-3-/- BMDCs have
delayed production in type I IFN and therefore, a likely delay in maturation. With few

137

exceptions, examination of cytokine profiles revealed a global delay in cytokine
production from IRF-3-/- BMDCs compared to WT following HSV-1 challenge (Fig 4.2).
In addition, upregulation of CD86 also lagged behind WT BMDCs following HSV-1
infection (Fig 4.3). Interestingly, treatment with IFNβ resulted in CD86 upregulation in
WT BMDCs but not in IRF-3-/- BMDCs. This data suggest a possible explanation for the
continued defect in IRF-3-/- BMDCs following IFN pretreatment. The lack of IRF-3
potentially hinders BMDC activation either through reduced IFN amplification, loss of an
IRF-3 dependent gene product, or absence of a signaling cascade that indicates infection.
In contrast, treatment with poly IC induced upregulation of CD86 in both WT and IRF-3/-

BMDC and provides evidence that pattern recognition contributes to BMDC

maturation.
Having determined an impact for IRF-3 dependent pathways on HSV-1 infection
both in vitro and in vivo, the pathways leading to HSV-1 recognition and subsequent IRF3 activation remained to be determined. Previous reports had identified numerous
sensors and adaptors involved in the recognition of HSV-1, yet none had been shown to
have an impact on viral replication. Using the BMDC cultures, a variety of immune
component knockouts were screened for their control of HSV-1 replication; IRF-3-/BMDCs served as a positive control for enhanced viral replication. The results
demonstrated that none of the tested immune knockouts recapitulated the in vitro
phenotype seen in IRF-3-/- BMDCs (Table 4.1). Known sensors and adaptors from the
toll-like receptor and RIG-I like receptor pathways had no significant increase in viral
replication when compared to control cells. These results suggest that either the pathway
involved in recognition of HSV-1 has yet to be identified or has yet to be tested. Another
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possibility is that multiple sensors and adaptors are involved in HSV-1 recognition and
compensate for the absence of another pathway.

Concluding Remarks
The studies herein demonstrate a role for IRF-3 in the control of HSV-1 infection
both in vitro and in vivo. The loss of IRF-3 directly impacts the kinetics and production
of type I IFN and thus renders IRF-3-/- cells and mice more susceptible to HSV-1
infection. The study illustrates the importance of IRF-3 mediated recognition pathways in
the control of viral infection. We hope that these experiments provide a foundation for
further examination of the early recognition pathways and provide novel insight into the
interaction between HSV-1 and immune host defenses.
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Figure 4.1. Preliminary growth curves from primary IRF-3-/- brain cell cultures.
Primary (A) cortical neurons and (B) astrocytes were infected with HSV-1 at MOI 0.01.
At indicated times post infection, samples were collected and assayed for viral replication
via plaque assay on Vero cells. Results shown are representative of two independent
experiments.

Figure 4.2. IRF-3-/- BMDCs have a global delay in cytokine production as compared
to WT BMDCs. WT and IRF‐3‐/‐ BMDCs were infected at MOI 5 and media harvested
at 3, 6, 9, and 12 hours post infection. Bead based cytokine assays (Bioplex, BioRad)
were performed and cytokine titers are expressed as pg/mL. Figures shown represent
average of three independent experiments.

Figure 4.3. Maturation was delayed in IRF-3-/- BMDCs as measured by CD 86
upregulation. BMDCs were mock treated, infected with HSV-1 MOI 5, or treated with
poly IC or 100 units IFNβ as specified. Twelve hours post infection, cell were harvested
and assayed by FACs. Cells were gated on CD11b positive, PI negative populations and
assayed for upregulation of CD86, a measurement of BMDC activation.

Table 4.1. Summary of immune deficient BMDCs challenged with HSV‐1 Infection.
BMDCs were infected at MOIs of 1 and 0.01 and viral titers assayed at 6, 24, and 48
hours post infection. Each immune deficient BMDC was scored for increase in viral
replication compared to control cells at either MOI or any time point.
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Figure 4.1. Preliminary growth curves from primary IRF-3-/- brain cell cultures.

141

Figure 4.2. IRF-3-/- BMDCs have a global delay in cytokine production as compared
to WT BMDCs.

142

Figure 4.3. Maturation was delayed in IRF-3-/- BMDCs as measured by CD 86
upregulation.

143

Table 4.1. Summary of immune deficient BMDCs challenged with HSV‐1 Infection.

Knockout BMDC

HSV-1 Infection
(relative to WT)

IRF-3-/-

Increased viral replication

IFNαβγR-/-

Increased viral replication

STAT-1-/-

Increased viral replication

IRF-7-/-

Equivalent to WT

MYD88-/-

Equivalent to WT

MYD88-/-, Trif-/-

Equivalent to WT

IPS-1-/-

Equivalent to WT

TLR-3-/-

Equivalent to WT

TLR-9-/-

Equivalent to WT

TLR-7-/-

Not Completed

RIG-I-/-

Equivalent to WT

MDA-5-/-

Equivalent to WT

MDA-5-/-, TLR-3-/-

Equivalent to WT

DAI-/-

Not Completed

STING-/-

Not Completed
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